<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:podcast="https://podcastindex.org/namespace/1.0"
    xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"
    xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:spotify="http://www.spotify.com/ns/rss">
    <channel>
        <title>Innovation4Alpha</title>
        <generator>Castos</generator>
        <atom:link href="https://feeds.castos.com/w87m0" rel="self" type="application/rss+xml" />
        <link>http://www.innovation4alpha.com</link>
        <description>Innovation4Alpha is a podcast dedicated to the intersection of finance, technology, leadership and healthcare innovation with the goal of both entertainment and education for our community.</description>
        <lastBuildDate>Wed, 17 Jul 2024 04:05:00 +0000</lastBuildDate>
        <language>en-us</language>
        <copyright>© 2024 AngelMD Media LLC</copyright>
        
        <spotify:limit recentCount="100" />
        
        <spotify:countryOfOrigin>
              
        </spotify:countryOfOrigin>
                    <image>
                <url>https://episodes.castos.com/65d77fbfef1e86-57254076/images/podcast/covers/c1a-3q87p-dd77j8pvaj4n-qfp8f8.jpg</url>
                <title>Innovation4Alpha</title>
                <link>http://www.innovation4alpha.com</link>
            </image>
                <itunes:subtitle>Innovation4Alpha is a podcast dedicated to the intersection of finance, technology, leadership and healthcare innovation with the goal of both entertainment and education for our community.</itunes:subtitle>
        <itunes:author>Innovation4Alpha</itunes:author>
        <itunes:type>episodic</itunes:type>
        <itunes:summary>Innovation4Alpha is a podcast dedicated to the intersection of finance, technology, leadership and healthcare innovation with the goal of both entertainment and education for our community.</itunes:summary>
        <itunes:owner>
            <itunes:name>tobin@innovation4alpha.com (Innovation4Alpha)</itunes:name>
            <itunes:email>tobin@innovation4alpha.com</itunes:email>
        </itunes:owner>
        <itunes:explicit>false</itunes:explicit>
                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/podcast/covers/c1a-3q87p-dd77j8pvaj4n-qfp8f8.jpg"></itunes:image>
        
                                    <itunes:category text="Arts" />
                                                <itunes:category text="Business" />
                    
                    <itunes:new-feed-url>https://feeds.castos.com/w87m0</itunes:new-feed-url>
                
        
        <podcast:locked>yes</podcast:locked>
                                    <item>
                <title>
                    <![CDATA[Lessons Learned as a Surgeon & Fund Investor]]>
                </title>
                <pubDate>Wed, 17 Jul 2024 04:05:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="true">
                    https://permalink.castos.com/podcast/58793/episode/1787121</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/lessons-learned-as-a-surgeon-fund-investor</link>
                                <description>
                                            <![CDATA[<p>In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA and is a GP in a venture capital fund. Dr. Eastlack shares the background of how he got into angel and venture investing and offers some insights on how they execute their fund.</p>
<p>Dr. Robert Eastlack was born in Wyoming, and grew up primarily in Alaska, before attending Stanford University.  He majored in Human Biology with focus on Neurophysiology, and while there was on the Stanford Men’s Swimming Team, serving as captain in his senior year.  After finishing his undergraduate studies, he stayed and joined the research team in the Cardiology Department before attending medical school nearer his family in Texas.  Following graduation from Baylor College of Medicine, he returned to California, where he and his wife both matched at UCSD for their residency training.  The Orthopaedic Surgery residency was combined with a year of research fellowship, and under the tutelage of Dr. Steven Garfin, he decided upon undertaking a spine fellowship at Mayo Clinic in Rochester, Minnesota.  Upon completion of the fellowship, Dr. Eastlack returned to San Diego, working with both UCSD and the San Diego Spine Foundation fellowship programs, as well as the UCSD Orthopedic Surgery Department as a Clinical Instructor.  <br /><br />In 2008, he moved to Scripps Clinic in the Division of Orthopedic Surgery, and continues to serve as a Consultant there.  He also acts as Co-Director for the spine fellowship training program that is managed by the San Diego Spine Foundation.  He is a member of the International Spine Study Group, focused on adult deformity and minimally invasive research, and undertakes clinical and basic science research at Scripps Clinic as well.  His clinical interests are in cervical reconstruction, minimally invasive spinal reconstruction, and complex deformity surgery.  His wife Jennifer Eastlack is a Dermatologist in San Diego, and they have five children.  His personal interests include coaching various sports teams (baseball, soccer, and basketball) on which his children play and playing golf, as well as co-managing a life science fund and medical device development.<br /><br /></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA and is a GP in a venture capital fund. Dr. Eastlack shares the background of how he got into angel and venture investing and offers some insights on how they execute their fund.
Dr. Robert Eastlack was born in Wyoming, and grew up primarily in Alaska, before attending Stanford University.  He majored in Human Biology with focus on Neurophysiology, and while there was on the Stanford Men’s Swimming Team, serving as captain in his senior year.  After finishing his undergraduate studies, he stayed and joined the research team in the Cardiology Department before attending medical school nearer his family in Texas.  Following graduation from Baylor College of Medicine, he returned to California, where he and his wife both matched at UCSD for their residency training.  The Orthopaedic Surgery residency was combined with a year of research fellowship, and under the tutelage of Dr. Steven Garfin, he decided upon undertaking a spine fellowship at Mayo Clinic in Rochester, Minnesota.  Upon completion of the fellowship, Dr. Eastlack returned to San Diego, working with both UCSD and the San Diego Spine Foundation fellowship programs, as well as the UCSD Orthopedic Surgery Department as a Clinical Instructor.  In 2008, he moved to Scripps Clinic in the Division of Orthopedic Surgery, and continues to serve as a Consultant there.  He also acts as Co-Director for the spine fellowship training program that is managed by the San Diego Spine Foundation.  He is a member of the International Spine Study Group, focused on adult deformity and minimally invasive research, and undertakes clinical and basic science research at Scripps Clinic as well.  His clinical interests are in cervical reconstruction, minimally invasive spinal reconstruction, and complex deformity surgery.  His wife Jennifer Eastlack is a Dermatologist in San Diego, and they have five children.  His personal interests include coaching various sports teams (baseball, soccer, and basketball) on which his children play and playing golf, as well as co-managing a life science fund and medical device development.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Lessons Learned as a Surgeon & Fund Investor]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA and is a GP in a venture capital fund. Dr. Eastlack shares the background of how he got into angel and venture investing and offers some insights on how they execute their fund.</p>
<p>Dr. Robert Eastlack was born in Wyoming, and grew up primarily in Alaska, before attending Stanford University.  He majored in Human Biology with focus on Neurophysiology, and while there was on the Stanford Men’s Swimming Team, serving as captain in his senior year.  After finishing his undergraduate studies, he stayed and joined the research team in the Cardiology Department before attending medical school nearer his family in Texas.  Following graduation from Baylor College of Medicine, he returned to California, where he and his wife both matched at UCSD for their residency training.  The Orthopaedic Surgery residency was combined with a year of research fellowship, and under the tutelage of Dr. Steven Garfin, he decided upon undertaking a spine fellowship at Mayo Clinic in Rochester, Minnesota.  Upon completion of the fellowship, Dr. Eastlack returned to San Diego, working with both UCSD and the San Diego Spine Foundation fellowship programs, as well as the UCSD Orthopedic Surgery Department as a Clinical Instructor.  <br /><br />In 2008, he moved to Scripps Clinic in the Division of Orthopedic Surgery, and continues to serve as a Consultant there.  He also acts as Co-Director for the spine fellowship training program that is managed by the San Diego Spine Foundation.  He is a member of the International Spine Study Group, focused on adult deformity and minimally invasive research, and undertakes clinical and basic science research at Scripps Clinic as well.  His clinical interests are in cervical reconstruction, minimally invasive spinal reconstruction, and complex deformity surgery.  His wife Jennifer Eastlack is a Dermatologist in San Diego, and they have five children.  His personal interests include coaching various sports teams (baseball, soccer, and basketball) on which his children play and playing golf, as well as co-managing a life science fund and medical device development.<br /><br /></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1787121/c1e-jg935sq75r7up9vo2-qdrm5xdohxm3-gbjf8f.m4a" length="26649412"
                        type="audio/x-m4a">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA and is a GP in a venture capital fund. Dr. Eastlack shares the background of how he got into angel and venture investing and offers some insights on how they execute their fund.
Dr. Robert Eastlack was born in Wyoming, and grew up primarily in Alaska, before attending Stanford University.  He majored in Human Biology with focus on Neurophysiology, and while there was on the Stanford Men’s Swimming Team, serving as captain in his senior year.  After finishing his undergraduate studies, he stayed and joined the research team in the Cardiology Department before attending medical school nearer his family in Texas.  Following graduation from Baylor College of Medicine, he returned to California, where he and his wife both matched at UCSD for their residency training.  The Orthopaedic Surgery residency was combined with a year of research fellowship, and under the tutelage of Dr. Steven Garfin, he decided upon undertaking a spine fellowship at Mayo Clinic in Rochester, Minnesota.  Upon completion of the fellowship, Dr. Eastlack returned to San Diego, working with both UCSD and the San Diego Spine Foundation fellowship programs, as well as the UCSD Orthopedic Surgery Department as a Clinical Instructor.  In 2008, he moved to Scripps Clinic in the Division of Orthopedic Surgery, and continues to serve as a Consultant there.  He also acts as Co-Director for the spine fellowship training program that is managed by the San Diego Spine Foundation.  He is a member of the International Spine Study Group, focused on adult deformity and minimally invasive research, and undertakes clinical and basic science research at Scripps Clinic as well.  His clinical interests are in cervical reconstruction, minimally invasive spinal reconstruction, and complex deformity surgery.  His wife Jennifer Eastlack is a Dermatologist in San Diego, and they have five children.  His personal interests include coaching various sports teams (baseball, soccer, and basketball) on which his children play and playing golf, as well as co-managing a life science fund and medical device development.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1787121/c1a-3q87p-v61dx06pc7xw-mjvigq.png"></itunes:image>
                                                                            <itunes:duration>00:31:16</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Petra Capital Properties]]>
                </title>
                <pubDate>Fri, 15 Dec 2023 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-14153740</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/petra-capital-properties</link>
                                <description>
                                            <![CDATA[<p><b>Petra Capital Properties</b> is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with a special emphasis on leveraging 1031 exchanges.  <br /><br />They combine the experience of a seasoned investment team with the quantitative analytics of a proprietary real estate technology platform.  The result is optimized portfolio construction with risk adjusted returns. <br /><br />In this 30-minute episode, Tobin Arthur talks with the firm founder (Brad Watt) about his background, an overview of 1031 exchanges and who this strategy is designed for.<br /><br />[Note: Brad Watt is Registered Financial Representative.  Securities are offered through Saxony Securities, Inc., Member FINRA/SIPC.]</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Petra Capital Properties is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with a special emphasis on leveraging 1031 exchanges.  They combine the experience of a seasoned investment team with the quantitative analytics of a proprietary real estate technology platform.  The result is optimized portfolio construction with risk adjusted returns. In this 30-minute episode, Tobin Arthur talks with the firm founder (Brad Watt) about his background, an overview of 1031 exchanges and who this strategy is designed for.[Note: Brad Watt is Registered Financial Representative.  Securities are offered through Saxony Securities, Inc., Member FINRA/SIPC.]]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Petra Capital Properties]]>
                </itunes:title>
                                    <itunes:episode>6</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><b>Petra Capital Properties</b> is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with a special emphasis on leveraging 1031 exchanges.  <br /><br />They combine the experience of a seasoned investment team with the quantitative analytics of a proprietary real estate technology platform.  The result is optimized portfolio construction with risk adjusted returns. <br /><br />In this 30-minute episode, Tobin Arthur talks with the firm founder (Brad Watt) about his background, an overview of 1031 exchanges and who this strategy is designed for.<br /><br />[Note: Brad Watt is Registered Financial Representative.  Securities are offered through Saxony Securities, Inc., Member FINRA/SIPC.]</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702552/c1e-1q158tj33m4uxrvx8-5rvvq9nkfk9k-sm9tm7.mp3" length="24211269"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Petra Capital Properties is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with a special emphasis on leveraging 1031 exchanges.  They combine the experience of a seasoned investment team with the quantitative analytics of a proprietary real estate technology platform.  The result is optimized portfolio construction with risk adjusted returns. In this 30-minute episode, Tobin Arthur talks with the firm founder (Brad Watt) about his background, an overview of 1031 exchanges and who this strategy is designed for.[Note: Brad Watt is Registered Financial Representative.  Securities are offered through Saxony Securities, Inc., Member FINRA/SIPC.]]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702552/c1a-3q87p-mq33976nikkp-x1riju.jpg"></itunes:image>
                                                                            <itunes:duration>00:33:36</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Beam Wellness - Blanketing Red Light Therapy]]>
                </title>
                <pubDate>Fri, 06 Oct 2023 18:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-13730285</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/beam-wellness-blanketing-red-light-therapy</link>
                                <description>
                                            <![CDATA[<p>Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in Dallas after launching within the SMU MBA and incubator programs.<br /><br />The company is leading with a blanket housing two variations of red light frequencies. They are appealing to spas and others who know the benefits of red light therapy and want to apply the same technology to a full body experience. Pre-orders are underway with a commercial launch coming soon.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in Dallas after launching within the SMU MBA and incubator programs.The company is leading with a blanket housing two variations of red light frequencies. They are appealing to spas and others who know the benefits of red light therapy and want to apply the same technology to a full body experience. Pre-orders are underway with a commercial launch coming soon.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Beam Wellness - Blanketing Red Light Therapy]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in Dallas after launching within the SMU MBA and incubator programs.<br /><br />The company is leading with a blanket housing two variations of red light frequencies. They are appealing to spas and others who know the benefits of red light therapy and want to apply the same technology to a full body experience. Pre-orders are underway with a commercial launch coming soon.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702553/c1e-3q87pt5001mckxzgd-zo771m05c4-2gvdq7.mp3" length="14233763"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in Dallas after launching within the SMU MBA and incubator programs.The company is leading with a blanket housing two variations of red light frequencies. They are appealing to spas and others who know the benefits of red light therapy and want to apply the same technology to a full body experience. Pre-orders are underway with a commercial launch coming soon.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702553/c1a-3q87p-7n5580j5sw56-k8lsg2.jpg"></itunes:image>
                                                                            <itunes:duration>00:19:44</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Torque3: Advancing Stroke Rehabilitation w/ VR]]>
                </title>
                <pubDate>Wed, 23 Aug 2023 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-13458106</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/torque3-advancing-stroke-rehabilitation-w-vr</link>
                                <description>
                                            <![CDATA[<p>Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. </p><p> A wealth of research over the last 30 years has strongly indicated that stroke recovery can be significantly improved through immersive stimulation and robotic assistance. </p><p>The Torque3 system leverages this research with an approach of uncompromising design and implementation combining a robotic chair and virtual reality.<br /><br />In this episode, Founder/CEO David Ellzey shares some of the science behind Torque3 and insights into where they are headed.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes.  A wealth of research over the last 30 years has strongly indicated that stroke recovery can be significantly improved through immersive stimulation and robotic assistance. The Torque3 system leverages this research with an approach of uncompromising design and implementation combining a robotic chair and virtual reality.In this episode, Founder/CEO David Ellzey shares some of the science behind Torque3 and insights into where they are headed.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Torque3: Advancing Stroke Rehabilitation w/ VR]]>
                </itunes:title>
                                    <itunes:episode>4</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. </p><p> A wealth of research over the last 30 years has strongly indicated that stroke recovery can be significantly improved through immersive stimulation and robotic assistance. </p><p>The Torque3 system leverages this research with an approach of uncompromising design and implementation combining a robotic chair and virtual reality.<br /><br />In this episode, Founder/CEO David Ellzey shares some of the science behind Torque3 and insights into where they are headed.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702555/c1e-52po7umgg88f0k11r-zo771m05c3wk-zpexxd.mp3" length="18177938"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes.  A wealth of research over the last 30 years has strongly indicated that stroke recovery can be significantly improved through immersive stimulation and robotic assistance. The Torque3 system leverages this research with an approach of uncompromising design and implementation combining a robotic chair and virtual reality.In this episode, Founder/CEO David Ellzey shares some of the science behind Torque3 and insights into where they are headed.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702555/c1a-3q87p-7n5580j5s6v0-yeagsy.jpg"></itunes:image>
                                                                            <itunes:duration>00:25:13</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Track, Hockey & Kids - Richard Lehman, MD (Orthopedic Surgeon )]]>
                </title>
                <pubDate>Fri, 21 Jul 2023 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-13263191</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/track-hockey-kids-richard-lehman-md-orthopedic-surgeon</link>
                                <description>
                                            <![CDATA[<p>Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole spectrum of sports, but has a special focus on track &amp; field and hockey. <br /><br />He is also an author with a new book underway and a previous book: How to Raise an Athlete (available on Amazon).<br /><br />Dr. Lehman grew up in Miami, Florida. He completed his training at Washington University and the University of Pennsylvania, and completed a sports medicine fellowship in 1986. He was a part owner of the National Hockey League Florida Panthers and has been the team physician for the Florida Panthers, Tampa Bay Lightening and St. Louis Blues. He has been a consulting physician for UCLA Track &amp; Field and has covered four Olympic Games, as well as seven Track &amp; Field World Championships.</p><p>Dr. Lehman was inducted into the St. Louis Sports Hall of Fame and the Missouri Sports Hall of Fame Class of 2012 and was on the Board of Directors of the Jackie Joyner-Kersee Youth Foundation, the medical director of Webster Surgery Center and the medical director of the U.S. Center for Sports Medicine. He has served on the Board of Governors for the National Hockey League and is on the St. Louis Sports Commission. His practice encompasses taking care of professional athletes at all levels and all sports, as well as Division college athletes.</p><p>Dr. Lehman has revolutionized cartilage regeneration techniques working in conjunction with Biomet to further growth and reconstruction of articular cartilage. He has written and lectured extensively on the subject, and has written three books on tennis injuries. He has published extensively in orthopedic literature and sports medicine. He is licensed in Missouri and California. He actively takes care of Track &amp; Field athletes from all over the world and professional athletes from North America.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole spectrum of sports, but has a special focus on track & field and hockey. He is also an author with a new book underway and a previous book: How to Raise an Athlete (available on Amazon).Dr. Lehman grew up in Miami, Florida. He completed his training at Washington University and the University of Pennsylvania, and completed a sports medicine fellowship in 1986. He was a part owner of the National Hockey League Florida Panthers and has been the team physician for the Florida Panthers, Tampa Bay Lightening and St. Louis Blues. He has been a consulting physician for UCLA Track & Field and has covered four Olympic Games, as well as seven Track & Field World Championships.Dr. Lehman was inducted into the St. Louis Sports Hall of Fame and the Missouri Sports Hall of Fame Class of 2012 and was on the Board of Directors of the Jackie Joyner-Kersee Youth Foundation, the medical director of Webster Surgery Center and the medical director of the U.S. Center for Sports Medicine. He has served on the Board of Governors for the National Hockey League and is on the St. Louis Sports Commission. His practice encompasses taking care of professional athletes at all levels and all sports, as well as Division college athletes.Dr. Lehman has revolutionized cartilage regeneration techniques working in conjunction with Biomet to further growth and reconstruction of articular cartilage. He has written and lectured extensively on the subject, and has written three books on tennis injuries. He has published extensively in orthopedic literature and sports medicine. He is licensed in Missouri and California. He actively takes care of Track & Field athletes from all over the world and professional athletes from North America.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Track, Hockey & Kids - Richard Lehman, MD (Orthopedic Surgeon )]]>
                </itunes:title>
                                    <itunes:episode>2</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole spectrum of sports, but has a special focus on track &amp; field and hockey. <br /><br />He is also an author with a new book underway and a previous book: How to Raise an Athlete (available on Amazon).<br /><br />Dr. Lehman grew up in Miami, Florida. He completed his training at Washington University and the University of Pennsylvania, and completed a sports medicine fellowship in 1986. He was a part owner of the National Hockey League Florida Panthers and has been the team physician for the Florida Panthers, Tampa Bay Lightening and St. Louis Blues. He has been a consulting physician for UCLA Track &amp; Field and has covered four Olympic Games, as well as seven Track &amp; Field World Championships.</p><p>Dr. Lehman was inducted into the St. Louis Sports Hall of Fame and the Missouri Sports Hall of Fame Class of 2012 and was on the Board of Directors of the Jackie Joyner-Kersee Youth Foundation, the medical director of Webster Surgery Center and the medical director of the U.S. Center for Sports Medicine. He has served on the Board of Governors for the National Hockey League and is on the St. Louis Sports Commission. His practice encompasses taking care of professional athletes at all levels and all sports, as well as Division college athletes.</p><p>Dr. Lehman has revolutionized cartilage regeneration techniques working in conjunction with Biomet to further growth and reconstruction of articular cartilage. He has written and lectured extensively on the subject, and has written three books on tennis injuries. He has published extensively in orthopedic literature and sports medicine. He is licensed in Missouri and California. He actively takes care of Track &amp; Field athletes from all over the world and professional athletes from North America.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702556/c1e-x5d42im88w2cn5op6-p800n2oki9o-zqmmj2.mp3" length="38138932"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole spectrum of sports, but has a special focus on track & field and hockey. He is also an author with a new book underway and a previous book: How to Raise an Athlete (available on Amazon).Dr. Lehman grew up in Miami, Florida. He completed his training at Washington University and the University of Pennsylvania, and completed a sports medicine fellowship in 1986. He was a part owner of the National Hockey League Florida Panthers and has been the team physician for the Florida Panthers, Tampa Bay Lightening and St. Louis Blues. He has been a consulting physician for UCLA Track & Field and has covered four Olympic Games, as well as seven Track & Field World Championships.Dr. Lehman was inducted into the St. Louis Sports Hall of Fame and the Missouri Sports Hall of Fame Class of 2012 and was on the Board of Directors of the Jackie Joyner-Kersee Youth Foundation, the medical director of Webster Surgery Center and the medical director of the U.S. Center for Sports Medicine. He has served on the Board of Governors for the National Hockey League and is on the St. Louis Sports Commission. His practice encompasses taking care of professional athletes at all levels and all sports, as well as Division college athletes.Dr. Lehman has revolutionized cartilage regeneration techniques working in conjunction with Biomet to further growth and reconstruction of articular cartilage. He has written and lectured extensively on the subject, and has written three books on tennis injuries. He has published extensively in orthopedic literature and sports medicine. He is licensed in Missouri and California. He actively takes care of Track & Field athletes from all over the world and professional athletes from North America.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702556/c1a-3q87p-v088v9onsn9j-pd1kr8.jpg"></itunes:image>
                                                                            <itunes:duration>00:52:56</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Pathkeeper: Next Generation Surgical Robot]]>
                </title>
                <pubDate>Fri, 21 Jul 2023 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-13263514</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/pathkeeper-next-generation-surgical-robot</link>
                                <description>
                                            <![CDATA[<p>PathKeeper is an innovative robotic company founded in Israel.<br /><br />The company's disruptive, proprietary technology provides laser-like accuracy for spinal procedures. The unique technology tracks the surgical tools and vertebrae independently to guide accurate implant positioning for  positive clinical outcomes.<br /><br />In this episode we visit with Erez Lampert the Founder of Pathkeeper and Ryan LeBlac who heads up their US Operations.<br /><br />Learn how this device reduces radiation exposure in patients and physicians, provides better guidance and does all of this while being a fraction of the cost of current systems and with an implant vendor agnostic approach.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[PathKeeper is an innovative robotic company founded in Israel.The company's disruptive, proprietary technology provides laser-like accuracy for spinal procedures. The unique technology tracks the surgical tools and vertebrae independently to guide accurate implant positioning for  positive clinical outcomes.In this episode we visit with Erez Lampert the Founder of Pathkeeper and Ryan LeBlac who heads up their US Operations.Learn how this device reduces radiation exposure in patients and physicians, provides better guidance and does all of this while being a fraction of the cost of current systems and with an implant vendor agnostic approach.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Pathkeeper: Next Generation Surgical Robot]]>
                </itunes:title>
                                    <itunes:episode>3</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>PathKeeper is an innovative robotic company founded in Israel.<br /><br />The company's disruptive, proprietary technology provides laser-like accuracy for spinal procedures. The unique technology tracks the surgical tools and vertebrae independently to guide accurate implant positioning for  positive clinical outcomes.<br /><br />In this episode we visit with Erez Lampert the Founder of Pathkeeper and Ryan LeBlac who heads up their US Operations.<br /><br />Learn how this device reduces radiation exposure in patients and physicians, provides better guidance and does all of this while being a fraction of the cost of current systems and with an implant vendor agnostic approach.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702558/c1e-v574gi9rr13bw9gxj-v088v9m1i9rd-japnsd.mp3" length="20298169"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[PathKeeper is an innovative robotic company founded in Israel.The company's disruptive, proprietary technology provides laser-like accuracy for spinal procedures. The unique technology tracks the surgical tools and vertebrae independently to guide accurate implant positioning for  positive clinical outcomes.In this episode we visit with Erez Lampert the Founder of Pathkeeper and Ryan LeBlac who heads up their US Operations.Learn how this device reduces radiation exposure in patients and physicians, provides better guidance and does all of this while being a fraction of the cost of current systems and with an implant vendor agnostic approach.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702558/c1a-3q87p-rommgj90hnpk-yycgfg.jpg"></itunes:image>
                                                                            <itunes:duration>00:28:09</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Vitro BioPharma]]>
                </title>
                <pubDate>Mon, 22 May 2023 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-12895263</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-vitro-biopharma</link>
                                <description>
                                            <![CDATA[<p>In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he spent decades helping build the financial juggernaut Janus.<br /><br />Vitro Biopharma has a goal to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market; and ultimately, to address well-established multi-billion-dollar commercial markets.</p><p>The team has over 30 years of drug discovery and development experience that has enabled them to identify and advance multiple product candidates from preclinical studies into clinical trials. Specifically, their extensive knowledge of immunology and inflammatory conditions informs their decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.  Visit them at www.vitrobiopharma.com</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he spent decades helping build the financial juggernaut Janus.Vitro Biopharma has a goal to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market; and ultimately, to address well-established multi-billion-dollar commercial markets.The team has over 30 years of drug discovery and development experience that has enabled them to identify and advance multiple product candidates from preclinical studies into clinical trials. Specifically, their extensive knowledge of immunology and inflammatory conditions informs their decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.  Visit them at www.vitrobiopharma.com]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Vitro BioPharma]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                    <itunes:season>3</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he spent decades helping build the financial juggernaut Janus.<br /><br />Vitro Biopharma has a goal to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market; and ultimately, to address well-established multi-billion-dollar commercial markets.</p><p>The team has over 30 years of drug discovery and development experience that has enabled them to identify and advance multiple product candidates from preclinical studies into clinical trials. Specifically, their extensive knowledge of immunology and inflammatory conditions informs their decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.  Visit them at www.vitrobiopharma.com</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702557/c1e-odgzobv00d8h8pvq1-1xgg2vjns9w4-jkcb1g.mp3" length="16679732"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he spent decades helping build the financial juggernaut Janus.Vitro Biopharma has a goal to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market; and ultimately, to address well-established multi-billion-dollar commercial markets.The team has over 30 years of drug discovery and development experience that has enabled them to identify and advance multiple product candidates from preclinical studies into clinical trials. Specifically, their extensive knowledge of immunology and inflammatory conditions informs their decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.  Visit them at www.vitrobiopharma.com]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702557/c1a-3q87p-33225ojzcd14-lhocc8.jpg"></itunes:image>
                                                                            <itunes:duration>00:23:08</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[HIPPO Health: Clinician Founded and Owned EMR for Care Teams (236)]]>
                </title>
                <pubDate>Tue, 20 Sep 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11356113</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/hippo-health-clinician-founded-and-owned-emr-for-care-teams-236</link>
                                <description>
                                            <![CDATA[<p>Hippo Health was founded by experienced emergency physicians who wanted to ease healthcare frustrations and make tele-health and excellent care coordination accessible to all.</p><p>Hippo Health is now offering providers the ability to build out their own personalized care networks to improve the modern day care experience for patients and providers.<br /><br />Founder, Kevin McGarvey, MD shares some of the latest updates on this rapidly growing tele-health platform including the recent addition of a seasoned CEO.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Hippo Health was founded by experienced emergency physicians who wanted to ease healthcare frustrations and make tele-health and excellent care coordination accessible to all.Hippo Health is now offering providers the ability to build out their own personalized care networks to improve the modern day care experience for patients and providers.Founder, Kevin McGarvey, MD shares some of the latest updates on this rapidly growing tele-health platform including the recent addition of a seasoned CEO.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[HIPPO Health: Clinician Founded and Owned EMR for Care Teams (236)]]>
                </itunes:title>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Hippo Health was founded by experienced emergency physicians who wanted to ease healthcare frustrations and make tele-health and excellent care coordination accessible to all.</p><p>Hippo Health is now offering providers the ability to build out their own personalized care networks to improve the modern day care experience for patients and providers.<br /><br />Founder, Kevin McGarvey, MD shares some of the latest updates on this rapidly growing tele-health platform including the recent addition of a seasoned CEO.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702559/c1e-d3q2gh6vv50apzn41-60pp8rmdi3j8-rabbpv.mp3" length="14624427"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Hippo Health was founded by experienced emergency physicians who wanted to ease healthcare frustrations and make tele-health and excellent care coordination accessible to all.Hippo Health is now offering providers the ability to build out their own personalized care networks to improve the modern day care experience for patients and providers.Founder, Kevin McGarvey, MD shares some of the latest updates on this rapidly growing tele-health platform including the recent addition of a seasoned CEO.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702559/c1a-3q87p-92kkgmz5u5jp-mknxc2.jpg"></itunes:image>
                                                                            <itunes:duration>00:20:17</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[SomnoSeal: Enhancing the CPAP Experience & Compliance (235)]]>
                </title>
                <pubDate>Fri, 16 Sep 2022 01:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11328469</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/somnoseal-enhancing-the-cpap-experience-compliance-235</link>
                                <description>
                                            <![CDATA[<p>Kimberly Hutchison, MD is a neurologist who specializes in Sleep Medicine. While there is expectation that someday the CPAP will be replaced as a sleep aid, it remains the Gold Standard. for now. Even though it's the best way to treat many patients, compliance remains a problem. To help with compliance, Dr. Hutchison has developed the SomnoSeal to provide a better fit for CPAP machines. Learn more about this product and about an entrepreneurial physician working to provide better outcomes for patients.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Kimberly Hutchison, MD is a neurologist who specializes in Sleep Medicine. While there is expectation that someday the CPAP will be replaced as a sleep aid, it remains the Gold Standard. for now. Even though it's the best way to treat many patients, compliance remains a problem. To help with compliance, Dr. Hutchison has developed the SomnoSeal to provide a better fit for CPAP machines. Learn more about this product and about an entrepreneurial physician working to provide better outcomes for patients.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[SomnoSeal: Enhancing the CPAP Experience & Compliance (235)]]>
                </itunes:title>
                                    <itunes:episode>35</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Kimberly Hutchison, MD is a neurologist who specializes in Sleep Medicine. While there is expectation that someday the CPAP will be replaced as a sleep aid, it remains the Gold Standard. for now. Even though it's the best way to treat many patients, compliance remains a problem. To help with compliance, Dr. Hutchison has developed the SomnoSeal to provide a better fit for CPAP machines. Learn more about this product and about an entrepreneurial physician working to provide better outcomes for patients.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702561/c1e-0qgpztjoo9rug03wq-49884301t6d4-ubbxgx.mp3" length="14004902"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Kimberly Hutchison, MD is a neurologist who specializes in Sleep Medicine. While there is expectation that someday the CPAP will be replaced as a sleep aid, it remains the Gold Standard. for now. Even though it's the best way to treat many patients, compliance remains a problem. To help with compliance, Dr. Hutchison has developed the SomnoSeal to provide a better fit for CPAP machines. Learn more about this product and about an entrepreneurial physician working to provide better outcomes for patients.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702561/c1a-3q87p-5rvvq9nkfv37-zgff0l.jpg"></itunes:image>
                                                                            <itunes:duration>00:19:25</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Lung Technologies: A scrappy team addressing DVTs. (234)]]>
                </title>
                <pubDate>Sat, 10 Sep 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11294969</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/lung-technologies-a-scrappy-team-addressing-dvts-234</link>
                                <description>
                                            <![CDATA[<p>Kerry Curran brings a career in medical device technology to a nimble startup leveraging student engineering skill to design products addressing post surgical Pulmonary Atelectasis and Deep Vein Thrombosis (DVT’s). While in it's early stages, this company is demonstrating how creative use of student skill and ingenuity, combined with a strong clinician feedback loop, can lead to useful innovation.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Kerry Curran brings a career in medical device technology to a nimble startup leveraging student engineering skill to design products addressing post surgical Pulmonary Atelectasis and Deep Vein Thrombosis (DVT’s). While in it's early stages, this company is demonstrating how creative use of student skill and ingenuity, combined with a strong clinician feedback loop, can lead to useful innovation.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Lung Technologies: A scrappy team addressing DVTs. (234)]]>
                </itunes:title>
                                    <itunes:episode>34</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Kerry Curran brings a career in medical device technology to a nimble startup leveraging student engineering skill to design products addressing post surgical Pulmonary Atelectasis and Deep Vein Thrombosis (DVT’s). While in it's early stages, this company is demonstrating how creative use of student skill and ingenuity, combined with a strong clinician feedback loop, can lead to useful innovation.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702560/c1e-x5d42im8825in143d-2o118x9ka84z-a2ls3b.mp3" length="7759640"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Kerry Curran brings a career in medical device technology to a nimble startup leveraging student engineering skill to design products addressing post surgical Pulmonary Atelectasis and Deep Vein Thrombosis (DVT’s). While in it's early stages, this company is demonstrating how creative use of student skill and ingenuity, combined with a strong clinician feedback loop, can lead to useful innovation.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702560/c1a-3q87p-gdqqj7g2ujr3-9akgs0.jpg"></itunes:image>
                                                                            <itunes:duration>00:10:45</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[NXgenPort: Advancing remote care of cancer patients requiring a port (233)]]>
                </title>
                <pubDate>Sat, 10 Sep 2022 18:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11294941</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/nxgenport-advancing-remote-care-of-cancer-patients-requiring-a-port-233</link>
                                <description>
                                            <![CDATA[<p>NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.<br /><br />In this episode,  Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.In this episode,  Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[NXgenPort: Advancing remote care of cancer patients requiring a port (233)]]>
                </itunes:title>
                                    <itunes:episode>33</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.<br /><br />In this episode,  Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702563/c1e-jg935sq1131hno305-p800n2o4u85v-vfykdc.mp3" length="14149767"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.In this episode,  Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702563/c1a-3q87p-5rvvq9n1cd9d-8qjnop.jpg"></itunes:image>
                                                                            <itunes:duration>00:19:37</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[David Kay, MD: Orthopedic Surgeon and Prolific Entrepreneur (232)]]>
                </title>
                <pubDate>Sat, 03 Sep 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11254566</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/david-kay-md-orthopedic-surgeon-and-prolific-entrepreneur-232-1</link>
                                <description>
                                            <![CDATA[<p>Dr. Kay is a Foot &amp; Ankle surgeon based in Ohio. Like many physicians, he and his colleagues saw better ways to treat patients and began to take steps to implement these ideas. The result is a long history of innovation, learning and hard work which now results in not one, but three companies in the pipeline. In this introductory discussion, you'll get a glimpse into Dr. Kay's formula, which includes getting some of the best specialized expertise in a given field involved in the venture. Interestingly, Dr. Kay's current ventures span 3 very different spaces: wound closure, ankle bracing and hand-held robotics.<br /><br />Any aspiring or current medtech entrepreneur will benefit from listening to this seasoned physician-inventor-entrepreneur.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Dr. Kay is a Foot & Ankle surgeon based in Ohio. Like many physicians, he and his colleagues saw better ways to treat patients and began to take steps to implement these ideas. The result is a long history of innovation, learning and hard work which now results in not one, but three companies in the pipeline. In this introductory discussion, you'll get a glimpse into Dr. Kay's formula, which includes getting some of the best specialized expertise in a given field involved in the venture. Interestingly, Dr. Kay's current ventures span 3 very different spaces: wound closure, ankle bracing and hand-held robotics.Any aspiring or current medtech entrepreneur will benefit from listening to this seasoned physician-inventor-entrepreneur.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[David Kay, MD: Orthopedic Surgeon and Prolific Entrepreneur (232)]]>
                </itunes:title>
                                    <itunes:episode>32</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Dr. Kay is a Foot &amp; Ankle surgeon based in Ohio. Like many physicians, he and his colleagues saw better ways to treat patients and began to take steps to implement these ideas. The result is a long history of innovation, learning and hard work which now results in not one, but three companies in the pipeline. In this introductory discussion, you'll get a glimpse into Dr. Kay's formula, which includes getting some of the best specialized expertise in a given field involved in the venture. Interestingly, Dr. Kay's current ventures span 3 very different spaces: wound closure, ankle bracing and hand-held robotics.<br /><br />Any aspiring or current medtech entrepreneur will benefit from listening to this seasoned physician-inventor-entrepreneur.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702562/c1e-v574gi9rrmnuw9kpn-04mm08o5fmdo-e2vkza.mp3" length="4907039"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Dr. Kay is a Foot & Ankle surgeon based in Ohio. Like many physicians, he and his colleagues saw better ways to treat patients and began to take steps to implement these ideas. The result is a long history of innovation, learning and hard work which now results in not one, but three companies in the pipeline. In this introductory discussion, you'll get a glimpse into Dr. Kay's formula, which includes getting some of the best specialized expertise in a given field involved in the venture. Interestingly, Dr. Kay's current ventures span 3 very different spaces: wound closure, ankle bracing and hand-held robotics.Any aspiring or current medtech entrepreneur will benefit from listening to this seasoned physician-inventor-entrepreneur.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702562/c1a-3q87p-1xgg2v34cn96-zxpckz.jpg"></itunes:image>
                                                                            <itunes:duration>00:06:47</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[AllCore360: Innovative & Effective Core Rehab & Conditioning (231)]]>
                </title>
                <pubDate>Sat, 27 Aug 2022 21:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11214186</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/allcore360-innovative-effective-core-rehab-conditioning-231-1</link>
                                <description>
                                            <![CDATA[<p>AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more efficient way. Scott Bertrund is the Founder and shares the story of the company and how it has evolved from a rehab focus to one that also includes rotational sports training and all-around health.<br /><br />The AllCore360 website lists locations across the country where you can find and experience this unique equipment. Physicians, Physical Therapists and Trainers can get more information on the company and product at their website.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more efficient way. Scott Bertrund is the Founder and shares the story of the company and how it has evolved from a rehab focus to one that also includes rotational sports training and all-around health.The AllCore360 website lists locations across the country where you can find and experience this unique equipment. Physicians, Physical Therapists and Trainers can get more information on the company and product at their website.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[AllCore360: Innovative & Effective Core Rehab & Conditioning (231)]]>
                </itunes:title>
                                    <itunes:episode>31</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more efficient way. Scott Bertrund is the Founder and shares the story of the company and how it has evolved from a rehab focus to one that also includes rotational sports training and all-around health.<br /><br />The AllCore360 website lists locations across the country where you can find and experience this unique equipment. Physicians, Physical Therapists and Trainers can get more information on the company and product at their website.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702564/c1e-v574gi9rrm8cw9jjj-92kkgmzrtpxk-1fgxpx.mp3" length="17995538"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more efficient way. Scott Bertrund is the Founder and shares the story of the company and how it has evolved from a rehab focus to one that also includes rotational sports training and all-around health.The AllCore360 website lists locations across the country where you can find and experience this unique equipment. Physicians, Physical Therapists and Trainers can get more information on the company and product at their website.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702564/c1a-3q87p-2o118x9nim95-jxgnrp.jpg"></itunes:image>
                                                                            <itunes:duration>00:24:57</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Pacific Echelon Security Services: Innovation & Hyper Growth in Physical Security (230)]]>
                </title>
                <pubDate>Wed, 24 Aug 2022 04:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11194013</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/pacific-echelon-security-services-innovation-hyper-growth-in-physical-security-230-1</link>
                                <description>
                                            <![CDATA[<p>Alex Stone is the Founder/CEO of Pacific Echelon Security Services, one of the fastest growing security companies in the United States.  The company is based on of Portland, ground zero in many ways, for the chaos that has erupted over the past few years.<br /><br />Combining both innovative community integration and cutting edge technology, Echelon is able to secure commercial properties with results that blow the competition away. Their solutions are appropriate for everything from multi-tenant housing to office buildings to hospital campuses and even executive protection.<br /><br />In this quick briefing, Co-host Yuri Sernande introduces Alex to the Innovation4Alpha community. In future discussions we'll get into the philosophy and tactics behind Echelons incredible success.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Alex Stone is the Founder/CEO of Pacific Echelon Security Services, one of the fastest growing security companies in the United States.  The company is based on of Portland, ground zero in many ways, for the chaos that has erupted over the past few years.Combining both innovative community integration and cutting edge technology, Echelon is able to secure commercial properties with results that blow the competition away. Their solutions are appropriate for everything from multi-tenant housing to office buildings to hospital campuses and even executive protection.In this quick briefing, Co-host Yuri Sernande introduces Alex to the Innovation4Alpha community. In future discussions we'll get into the philosophy and tactics behind Echelons incredible success.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Pacific Echelon Security Services: Innovation & Hyper Growth in Physical Security (230)]]>
                </itunes:title>
                                    <itunes:episode>30</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Alex Stone is the Founder/CEO of Pacific Echelon Security Services, one of the fastest growing security companies in the United States.  The company is based on of Portland, ground zero in many ways, for the chaos that has erupted over the past few years.<br /><br />Combining both innovative community integration and cutting edge technology, Echelon is able to secure commercial properties with results that blow the competition away. Their solutions are appropriate for everything from multi-tenant housing to office buildings to hospital campuses and even executive protection.<br /><br />In this quick briefing, Co-host Yuri Sernande introduces Alex to the Innovation4Alpha community. In future discussions we'll get into the philosophy and tactics behind Echelons incredible success.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702565/c1e-7w79ds42204td9rz5-wnvv4r28b67-ucrged.mp3" length="20218690"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Alex Stone is the Founder/CEO of Pacific Echelon Security Services, one of the fastest growing security companies in the United States.  The company is based on of Portland, ground zero in many ways, for the chaos that has erupted over the past few years.Combining both innovative community integration and cutting edge technology, Echelon is able to secure commercial properties with results that blow the competition away. Their solutions are appropriate for everything from multi-tenant housing to office buildings to hospital campuses and even executive protection.In this quick briefing, Co-host Yuri Sernande introduces Alex to the Innovation4Alpha community. In future discussions we'll get into the philosophy and tactics behind Echelons incredible success.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702565/c1a-3q87p-jkwwx782ip81-vfym4q.jpg"></itunes:image>
                                                                            <itunes:duration>00:28:03</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Mark Cherney: Founder, US Urology Partners - The State of Private Equity (229)]]>
                </title>
                <pubDate>Sun, 21 Aug 2022 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11173142</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/mark-cherney-founder-us-urology-partners-the-state-of-private-equity-229-1</link>
                                <description>
                                            <![CDATA[<p>Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role into the Executive Chair role and in this brief discussion he introduces some of the headwinds ahead for both Private Equity &amp; the medical practices that have been part of PE roll-ups.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role into the Executive Chair role and in this brief discussion he introduces some of the headwinds ahead for both Private Equity & the medical practices that have been part of PE roll-ups.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Mark Cherney: Founder, US Urology Partners - The State of Private Equity (229)]]>
                </itunes:title>
                                    <itunes:episode>229</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role into the Executive Chair role and in this brief discussion he introduces some of the headwinds ahead for both Private Equity &amp; the medical practices that have been part of PE roll-ups.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702566/c1e-3q87pt5004kikx1vq-xmppk014f4j5-qfma1j.mp3" length="10009909"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role into the Executive Chair role and in this brief discussion he introduces some of the headwinds ahead for both Private Equity & the medical practices that have been part of PE roll-ups.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702566/c1a-3q87p-33225ordik33-jrqt2u.jpg"></itunes:image>
                                                                            <itunes:duration>00:13:52</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Star Harbor: Accelerating innovation through space education, training and research (228)]]>
                </title>
                <pubDate>Tue, 16 Aug 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11151008</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/star-harbor-accelerating-innovation-through-space-education-training-and-research-228-1</link>
                                <description>
                                            <![CDATA[<p>Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how its cross disciplinary work will accelerate innovation in everything from medicine to ag-tech etc.<br /><br />As an example of the cross disciplinary work ahead, the CU Anschutz School of Medicine even has a space oriented medicine program described as follows: The University of Colorado Space and Extreme Environment Medicine Program is an interdisciplinary collaboration between experts in medicine, engineering, spaceflight, education, simulation, and remote environment expedition support.<br /><br />Star Harbor is not your typical startup with significant real estate, build out and staffing costs. To get there, it is employing a mix of public-private funding resources as it seeks to become a key resource for space training as the industry accelerates. While training astronauts and consumer passengers for missions is a part of the organization, a great deal of effort will be dedicated to certifying materials for space missions and facilitating research. The 50+ acre campus will house all of the equipment and lodging facilities required to do this in one place.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how its cross disciplinary work will accelerate innovation in everything from medicine to ag-tech etc.As an example of the cross disciplinary work ahead, the CU Anschutz School of Medicine even has a space oriented medicine program described as follows: The University of Colorado Space and Extreme Environment Medicine Program is an interdisciplinary collaboration between experts in medicine, engineering, spaceflight, education, simulation, and remote environment expedition support.Star Harbor is not your typical startup with significant real estate, build out and staffing costs. To get there, it is employing a mix of public-private funding resources as it seeks to become a key resource for space training as the industry accelerates. While training astronauts and consumer passengers for missions is a part of the organization, a great deal of effort will be dedicated to certifying materials for space missions and facilitating research. The 50+ acre campus will house all of the equipment and lodging facilities required to do this in one place.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Star Harbor: Accelerating innovation through space education, training and research (228)]]>
                </itunes:title>
                                    <itunes:episode>27</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how its cross disciplinary work will accelerate innovation in everything from medicine to ag-tech etc.<br /><br />As an example of the cross disciplinary work ahead, the CU Anschutz School of Medicine even has a space oriented medicine program described as follows: The University of Colorado Space and Extreme Environment Medicine Program is an interdisciplinary collaboration between experts in medicine, engineering, spaceflight, education, simulation, and remote environment expedition support.<br /><br />Star Harbor is not your typical startup with significant real estate, build out and staffing costs. To get there, it is employing a mix of public-private funding resources as it seeks to become a key resource for space training as the industry accelerates. While training astronauts and consumer passengers for missions is a part of the organization, a great deal of effort will be dedicated to certifying materials for space missions and facilitating research. The 50+ acre campus will house all of the equipment and lodging facilities required to do this in one place.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702567/c1e-p51x3i500rwtmnndd-04mm08oph61q-1dsi2r.mp3" length="23947633"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how its cross disciplinary work will accelerate innovation in everything from medicine to ag-tech etc.As an example of the cross disciplinary work ahead, the CU Anschutz School of Medicine even has a space oriented medicine program described as follows: The University of Colorado Space and Extreme Environment Medicine Program is an interdisciplinary collaboration between experts in medicine, engineering, spaceflight, education, simulation, and remote environment expedition support.Star Harbor is not your typical startup with significant real estate, build out and staffing costs. To get there, it is employing a mix of public-private funding resources as it seeks to become a key resource for space training as the industry accelerates. While training astronauts and consumer passengers for missions is a part of the organization, a great deal of effort will be dedicated to certifying materials for space missions and facilitating research. The 50+ acre campus will house all of the equipment and lodging facilities required to do this in one place.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702567/c1a-3q87p-8m778n1runnq-kj91sv.jpg"></itunes:image>
                                                                            <itunes:duration>00:33:14</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Ai Medica: Turbo-charging EHRs for Better Outcomes & More (227)]]>
                </title>
                <pubDate>Sat, 30 Jul 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-11054072</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/ai-medica-turbo-charging-ehrs-for-better-outcomes-more-227-1</link>
                                <description>
                                            <![CDATA[<p>Ai Medica makes it easy to create clinical and economic value from EHR data using evidence based medicine. They have built a platform on SMART on FHIR interoperability standards that allows them to integrate evidence based calculators into the EHR in a matter of weeks. <br /><br />Their mission is to simplify evidence based clinical work flows using EHR data to drive better application of evidence to care for patients, decreased effort and burnout for physicians, and better integration, reporting and compliance on evidence based initiatives for health systems.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Ai Medica makes it easy to create clinical and economic value from EHR data using evidence based medicine. They have built a platform on SMART on FHIR interoperability standards that allows them to integrate evidence based calculators into the EHR in a matter of weeks. Their mission is to simplify evidence based clinical work flows using EHR data to drive better application of evidence to care for patients, decreased effort and burnout for physicians, and better integration, reporting and compliance on evidence based initiatives for health systems.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Ai Medica: Turbo-charging EHRs for Better Outcomes & More (227)]]>
                </itunes:title>
                                    <itunes:episode>27</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Ai Medica makes it easy to create clinical and economic value from EHR data using evidence based medicine. They have built a platform on SMART on FHIR interoperability standards that allows them to integrate evidence based calculators into the EHR in a matter of weeks. <br /><br />Their mission is to simplify evidence based clinical work flows using EHR data to drive better application of evidence to care for patients, decreased effort and burnout for physicians, and better integration, reporting and compliance on evidence based initiatives for health systems.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702568/c1e-r583rijmm5dt2xo2g-33225ormsx02-ijd7fy.mp3" length="20948077"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Ai Medica makes it easy to create clinical and economic value from EHR data using evidence based medicine. They have built a platform on SMART on FHIR interoperability standards that allows them to integrate evidence based calculators into the EHR in a matter of weeks. Their mission is to simplify evidence based clinical work flows using EHR data to drive better application of evidence to care for patients, decreased effort and burnout for physicians, and better integration, reporting and compliance on evidence based initiatives for health systems.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702568/c1a-3q87p-jkwwx783sqj0-xjscwt.jpg"></itunes:image>
                                                                            <itunes:duration>00:29:03</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[MRG Health: Chronic Care Management on a New Level (226)]]>
                </title>
                <pubDate>Sat, 16 Jul 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10971802</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/mrg-health-chronic-care-management-on-a-new-level-226-1</link>
                                <description>
                                            <![CDATA[<p>MRG address issues involving access to care, chronic disease management, patient adherence &amp; compliance to doctors orders, and frees up clinicians time through leveraging technology so they can better monitor and manage larger amounts of patients more effectively and efficiently.<br /><br />Smart Care 360 is a complete and comprehensive care management platform that allows physicians and caregivers to manage the full continuum of care. By continuous monitoring of a patient’s vitals, nutrition, medication, and daily living activities clinicians see a holistic picture of the patient. Using their AI and threshold capabilities they provide a more proactive approach for care decisions and can alert caregivers to any change in condition. <br /><br />The platform is a complete solution that includes auto messaging, reminders to patients, 2 way communication, video conferencing with vitals displayed in real time -- all recorded and integrated into any EMR. With MRG Care 360, there is a single view of everything on a patient, with alerts, thresholds, and continuous access for patients and physicians to each other. <br /><br />The MRG real-time RPM Management Solution increases staffing efficiency, reduces doctor and nurse burnout and provides more patient info with instant access to the patients and staff. The platform was developed after 2+ years of R&amp;D, and being involved in 4 very in depth Texas based studies on major clinical / operational needs in specific specialties &amp; chronic diseases throughout rural, urban, and metro geographic regions. The data was compiled, and prioritization of our capabilities was built on a code-less drag and drop UX/UI with decision tree logic that allows simple patient planning, customization and flexibility based on the HCO's needs which also promotes efficient and scalable deployment solutions for large variable patient groups based on the specific specialty, disease, or vertical market needs.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[MRG address issues involving access to care, chronic disease management, patient adherence & compliance to doctors orders, and frees up clinicians time through leveraging technology so they can better monitor and manage larger amounts of patients more effectively and efficiently.Smart Care 360 is a complete and comprehensive care management platform that allows physicians and caregivers to manage the full continuum of care. By continuous monitoring of a patient’s vitals, nutrition, medication, and daily living activities clinicians see a holistic picture of the patient. Using their AI and threshold capabilities they provide a more proactive approach for care decisions and can alert caregivers to any change in condition. The platform is a complete solution that includes auto messaging, reminders to patients, 2 way communication, video conferencing with vitals displayed in real time -- all recorded and integrated into any EMR. With MRG Care 360, there is a single view of everything on a patient, with alerts, thresholds, and continuous access for patients and physicians to each other. The MRG real-time RPM Management Solution increases staffing efficiency, reduces doctor and nurse burnout and provides more patient info with instant access to the patients and staff. The platform was developed after 2+ years of R&D, and being involved in 4 very in depth Texas based studies on major clinical / operational needs in specific specialties & chronic diseases throughout rural, urban, and metro geographic regions. The data was compiled, and prioritization of our capabilities was built on a code-less drag and drop UX/UI with decision tree logic that allows simple patient planning, customization and flexibility based on the HCO's needs which also promotes efficient and scalable deployment solutions for large variable patient groups based on the specific specialty, disease, or vertical market needs.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[MRG Health: Chronic Care Management on a New Level (226)]]>
                </itunes:title>
                                    <itunes:episode>26</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>MRG address issues involving access to care, chronic disease management, patient adherence &amp; compliance to doctors orders, and frees up clinicians time through leveraging technology so they can better monitor and manage larger amounts of patients more effectively and efficiently.<br /><br />Smart Care 360 is a complete and comprehensive care management platform that allows physicians and caregivers to manage the full continuum of care. By continuous monitoring of a patient’s vitals, nutrition, medication, and daily living activities clinicians see a holistic picture of the patient. Using their AI and threshold capabilities they provide a more proactive approach for care decisions and can alert caregivers to any change in condition. <br /><br />The platform is a complete solution that includes auto messaging, reminders to patients, 2 way communication, video conferencing with vitals displayed in real time -- all recorded and integrated into any EMR. With MRG Care 360, there is a single view of everything on a patient, with alerts, thresholds, and continuous access for patients and physicians to each other. <br /><br />The MRG real-time RPM Management Solution increases staffing efficiency, reduces doctor and nurse burnout and provides more patient info with instant access to the patients and staff. The platform was developed after 2+ years of R&amp;D, and being involved in 4 very in depth Texas based studies on major clinical / operational needs in specific specialties &amp; chronic diseases throughout rural, urban, and metro geographic regions. The data was compiled, and prioritization of our capabilities was built on a code-less drag and drop UX/UI with decision tree logic that allows simple patient planning, customization and flexibility based on the HCO's needs which also promotes efficient and scalable deployment solutions for large variable patient groups based on the specific specialty, disease, or vertical market needs.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702569/c1e-7w79ds4220mcd82xn-qxnnp73vb21v-zaeuho.mp3" length="19196465"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[MRG address issues involving access to care, chronic disease management, patient adherence & compliance to doctors orders, and frees up clinicians time through leveraging technology so they can better monitor and manage larger amounts of patients more effectively and efficiently.Smart Care 360 is a complete and comprehensive care management platform that allows physicians and caregivers to manage the full continuum of care. By continuous monitoring of a patient’s vitals, nutrition, medication, and daily living activities clinicians see a holistic picture of the patient. Using their AI and threshold capabilities they provide a more proactive approach for care decisions and can alert caregivers to any change in condition. The platform is a complete solution that includes auto messaging, reminders to patients, 2 way communication, video conferencing with vitals displayed in real time -- all recorded and integrated into any EMR. With MRG Care 360, there is a single view of everything on a patient, with alerts, thresholds, and continuous access for patients and physicians to each other. The MRG real-time RPM Management Solution increases staffing efficiency, reduces doctor and nurse burnout and provides more patient info with instant access to the patients and staff. The platform was developed after 2+ years of R&D, and being involved in 4 very in depth Texas based studies on major clinical / operational needs in specific specialties & chronic diseases throughout rural, urban, and metro geographic regions. The data was compiled, and prioritization of our capabilities was built on a code-less drag and drop UX/UI with decision tree logic that allows simple patient planning, customization and flexibility based on the HCO's needs which also promotes efficient and scalable deployment solutions for large variable patient groups based on the specific specialty, disease, or vertical market needs.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702569/c1a-3q87p-v088v9m4fj91-ysqlnn.jpg"></itunes:image>
                                                                            <itunes:duration>00:26:37</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[TearSolutions: Naturally Treating Dry Eye (225)]]>
                </title>
                <pubDate>Mon, 04 Jul 2022 21:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10903682</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/tearsolutions-naturally-treating-dry-eye-225-1</link>
                                <description>
                                            <![CDATA[<p>TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). <br /><br />The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[TearSolutions: Naturally Treating Dry Eye (225)]]>
                </itunes:title>
                                    <itunes:episode>25</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). <br /><br />The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702570/c1e-g0xz8i3wwk0s25938-4988430ohr3-azmxc8.mp3" length="16828882"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702570/c1a-3q87p-4988430mcmqo-dgearl.jpg"></itunes:image>
                                                                            <itunes:duration>00:23:20</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Sage Medical: Bringing Intelligence to Medical Coding & Billing (224)]]>
                </title>
                <pubDate>Wed, 29 Jun 2022 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10877113</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/sage-medical-bringing-intelligence-to-medical-coding-billing-224-1</link>
                                <description>
                                            <![CDATA[<p>With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%. The easy-to-use mobile app processes in real-time, eliminates coding &amp; billing errors while increasing revenue by $250k+ ARR.<br /><br />The company is raising a Seed investment round and their story can be heard here: <br /><br /><b>Online audio pitch deck:</b> <a href="https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0">https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0</a> </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%. The easy-to-use mobile app processes in real-time, eliminates coding & billing errors while increasing revenue by $250k+ ARR.The company is raising a Seed investment round and their story can be heard here: Online audio pitch deck: https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0 ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Sage Medical: Bringing Intelligence to Medical Coding & Billing (224)]]>
                </itunes:title>
                                    <itunes:episode>24</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%. The easy-to-use mobile app processes in real-time, eliminates coding &amp; billing errors while increasing revenue by $250k+ ARR.<br /><br />The company is raising a Seed investment round and their story can be heard here: <br /><br /><b>Online audio pitch deck:</b> <a href="https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0">https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0</a> </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702571/c1e-w5k81irzz0xu03wr8-8m778n10hz4d-7xpfim.mp3" length="16481529"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%. The easy-to-use mobile app processes in real-time, eliminates coding & billing errors while increasing revenue by $250k+ ARR.The company is raising a Seed investment round and their story can be heard here: Online audio pitch deck: https://www.dropbox.com/s/fv4q02s642zpn8u/Sage%20Medical%20-%2003%3A2022%20Pitch.mp4?dl=0 ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702571/c1a-3q87p-qxnnp731i4z7-a9vgn6.jpg"></itunes:image>
                                                                            <itunes:duration>00:22:51</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Improving Emergency Dental Care: Dentriage (222)]]>
                </title>
                <pubDate>Sat, 11 Jun 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10775466</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/improving-emergency-dental-care-dentriage-222-1</link>
                                <description>
                                            <![CDATA[<p>DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent and non-urgent dental issues using Tele-Dentistry. DenTriage enables consumers to have urgent questions answered, obtain a video consult with a dentist, search for nearby dentists, and make appointments with ease. <br /><br />DenTriage is working to improve ease of access to dental care and as a result, a reduction of no shows and unfilled appointments for dental practices. Improved access to urgent dental evaluation will lead to reduction in dental related ER visits and reduced overall cost of dental care for insurers and private individuals.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent and non-urgent dental issues using Tele-Dentistry. DenTriage enables consumers to have urgent questions answered, obtain a video consult with a dentist, search for nearby dentists, and make appointments with ease. DenTriage is working to improve ease of access to dental care and as a result, a reduction of no shows and unfilled appointments for dental practices. Improved access to urgent dental evaluation will lead to reduction in dental related ER visits and reduced overall cost of dental care for insurers and private individuals.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Improving Emergency Dental Care: Dentriage (222)]]>
                </itunes:title>
                                    <itunes:episode>22</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent and non-urgent dental issues using Tele-Dentistry. DenTriage enables consumers to have urgent questions answered, obtain a video consult with a dentist, search for nearby dentists, and make appointments with ease. <br /><br />DenTriage is working to improve ease of access to dental care and as a result, a reduction of no shows and unfilled appointments for dental practices. Improved access to urgent dental evaluation will lead to reduction in dental related ER visits and reduced overall cost of dental care for insurers and private individuals.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702573/c1e-7w79ds4220xtd8omq-rommgj9gf9og-halb4l.mp3" length="18831959"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent and non-urgent dental issues using Tele-Dentistry. DenTriage enables consumers to have urgent questions answered, obtain a video consult with a dentist, search for nearby dentists, and make appointments with ease. DenTriage is working to improve ease of access to dental care and as a result, a reduction of no shows and unfilled appointments for dental practices. Improved access to urgent dental evaluation will lead to reduction in dental related ER visits and reduced overall cost of dental care for insurers and private individuals.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702573/c1a-3q87p-1xgg2v32tv8-955vrv.jpg"></itunes:image>
                                                                            <itunes:duration>00:26:07</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[From Ukraine to Uganda - Project Cure Delivers Critical Medical Equipment and Supplies (223)]]>
                </title>
                <pubDate>Sat, 11 Jun 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10775525</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/from-ukraine-to-uganda-project-cure-delivers-critical-medical-equipment-and-supplies-223-1</link>
                                <description>
                                            <![CDATA[<p>Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise of Project Cure.<br /><br />Project C.U.R.E. was founded in 1987 to address the staggering shortage of medical resources around the world. Project C.U.R.E. has become the world’s largest distributor of donated medical supplies, equipment and services to doctors and nurses serving the sick and dying in more than 135 countries.<br /><br />Each week Project C.U.R.E. delivers approximately three to five semi-truck-sized ocean containers packed with the medical equipment and supplies desperately needed to save lives in hospitals and clinics in resource-limited countries. In addition, each year hundreds of healthcare professionals travel with Project C.U.R.E. to provide medical treatment to communities in need and training to those dedicated to serving them. Project C.U.R.E. is supported by over 30,000 volunteers annually and operates distribution warehouses in seven U.S. cities.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise of Project Cure.Project C.U.R.E. was founded in 1987 to address the staggering shortage of medical resources around the world. Project C.U.R.E. has become the world’s largest distributor of donated medical supplies, equipment and services to doctors and nurses serving the sick and dying in more than 135 countries.Each week Project C.U.R.E. delivers approximately three to five semi-truck-sized ocean containers packed with the medical equipment and supplies desperately needed to save lives in hospitals and clinics in resource-limited countries. In addition, each year hundreds of healthcare professionals travel with Project C.U.R.E. to provide medical treatment to communities in need and training to those dedicated to serving them. Project C.U.R.E. is supported by over 30,000 volunteers annually and operates distribution warehouses in seven U.S. cities.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[From Ukraine to Uganda - Project Cure Delivers Critical Medical Equipment and Supplies (223)]]>
                </itunes:title>
                                    <itunes:episode>23</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise of Project Cure.<br /><br />Project C.U.R.E. was founded in 1987 to address the staggering shortage of medical resources around the world. Project C.U.R.E. has become the world’s largest distributor of donated medical supplies, equipment and services to doctors and nurses serving the sick and dying in more than 135 countries.<br /><br />Each week Project C.U.R.E. delivers approximately three to five semi-truck-sized ocean containers packed with the medical equipment and supplies desperately needed to save lives in hospitals and clinics in resource-limited countries. In addition, each year hundreds of healthcare professionals travel with Project C.U.R.E. to provide medical treatment to communities in need and training to those dedicated to serving them. Project C.U.R.E. is supported by over 30,000 volunteers annually and operates distribution warehouses in seven U.S. cities.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702572/c1e-n5mzxi511jqh90473-2o118x98f0zg-dfwmee.mp3" length="29948371"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise of Project Cure.Project C.U.R.E. was founded in 1987 to address the staggering shortage of medical resources around the world. Project C.U.R.E. has become the world’s largest distributor of donated medical supplies, equipment and services to doctors and nurses serving the sick and dying in more than 135 countries.Each week Project C.U.R.E. delivers approximately three to five semi-truck-sized ocean containers packed with the medical equipment and supplies desperately needed to save lives in hospitals and clinics in resource-limited countries. In addition, each year hundreds of healthcare professionals travel with Project C.U.R.E. to provide medical treatment to communities in need and training to those dedicated to serving them. Project C.U.R.E. is supported by over 30,000 volunteers annually and operates distribution warehouses in seven U.S. cities.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702572/c1a-3q87p-o8rr02xphwn2-4tsgib.jpg"></itunes:image>
                                                                            <itunes:duration>00:41:34</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Clint McGill: Mental Toughness for Youth Athletes (221)]]>
                </title>
                <pubDate>Sun, 05 Jun 2022 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10739206</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/clint-mcgill-mental-toughness-for-youth-athletes-221-1</link>
                                <description>
                                            <![CDATA[<p>Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself, Clint was like many parents involved with their kid's sports activities...but he decided to apply well proven mental toughness tips and tools to help his kids and others. The result is the Bulletproof Hitter Educational Program and Baseball Notes.<br /><br />In this discussion, Clint shares his experience launching an educational programming business and comments on what worked and what didn't. Any parent with kids in sports, and any entrepreneur trying to figure out how to make social media work for them, will find this episode interesting.<br /><br />Check out some of Clint's terrific work:</p><ul><li><a href="https://baseballnotes.com/">Baseball Notes</a></li><li><a href="https://baseballnotes.com/the-bulletproof-hitter-program/">Bulletproof Hitter</a></li></ul>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself, Clint was like many parents involved with their kid's sports activities...but he decided to apply well proven mental toughness tips and tools to help his kids and others. The result is the Bulletproof Hitter Educational Program and Baseball Notes.In this discussion, Clint shares his experience launching an educational programming business and comments on what worked and what didn't. Any parent with kids in sports, and any entrepreneur trying to figure out how to make social media work for them, will find this episode interesting.Check out some of Clint's terrific work:Baseball NotesBulletproof Hitter]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Clint McGill: Mental Toughness for Youth Athletes (221)]]>
                </itunes:title>
                                    <itunes:episode>21</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself, Clint was like many parents involved with their kid's sports activities...but he decided to apply well proven mental toughness tips and tools to help his kids and others. The result is the Bulletproof Hitter Educational Program and Baseball Notes.<br /><br />In this discussion, Clint shares his experience launching an educational programming business and comments on what worked and what didn't. Any parent with kids in sports, and any entrepreneur trying to figure out how to make social media work for them, will find this episode interesting.<br /><br />Check out some of Clint's terrific work:</p><ul><li><a href="https://baseballnotes.com/">Baseball Notes</a></li><li><a href="https://baseballnotes.com/the-bulletproof-hitter-program/">Bulletproof Hitter</a></li></ul>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702574/c1e-52po7umgg4pc0k19g-qxnnp73xsnnw-lmp2mu.mp3" length="29409850"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself, Clint was like many parents involved with their kid's sports activities...but he decided to apply well proven mental toughness tips and tools to help his kids and others. The result is the Bulletproof Hitter Educational Program and Baseball Notes.In this discussion, Clint shares his experience launching an educational programming business and comments on what worked and what didn't. Any parent with kids in sports, and any entrepreneur trying to figure out how to make social media work for them, will find this episode interesting.Check out some of Clint's terrific work:Baseball NotesBulletproof Hitter]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702574/c1a-3q87p-k5xxoqvotr9k-9mk3gi.jpg"></itunes:image>
                                                                            <itunes:duration>00:40:49</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Neobe: Battling Cancer With Safe Bacteria (220)]]>
                </title>
                <pubDate>Tue, 31 May 2022 18:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10713575</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/neobe-battling-cancer-with-safe-bacteria-220-1</link>
                                <description>
                                            <![CDATA[<p>Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. <br /><br />Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. <br /><br />It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. <br /><br />During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Neobe: Battling Cancer With Safe Bacteria (220)]]>
                </itunes:title>
                                    <itunes:episode>20</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. <br /><br />Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. <br /><br />It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. <br /><br />During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702575/c1e-m2njdun339muwvvr8-92kkgmz2hj6w-uwikip.mp3" length="22395832"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702575/c1a-3q87p-5rvvq9nrszow-wkssbh.jpg"></itunes:image>
                                                                            <itunes:duration>00:31:04</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Lazurite: The Medical Device Company Turning the OR Wireless (219)]]>
                </title>
                <pubDate>Mon, 30 May 2022 00:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10702808</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/lazurite-the-medical-device-company-turning-the-or-wireless-219-1</link>
                                <description>
                                            <![CDATA[<p>In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get a glimpse into where its headed.<br /><br />For Lazurite’s inaugural device, the necessity of safety served as the mother of invention. While observing a surgery in 2015, CEO and Cofounder Eugene Malinskiy watched helplessly as a physician’s assistant tripped and fell over cables connected to the surgical tower. The accident drew Eugene’s attention to two cables in particular: the light and power cables that connected at one end to the surgical tower, snaked across the patient into the sterile field, and connected at the other end to the<br />surgical camera.<br /><br />The ArthroFree wireless surgical camera system allows surgeons to perform wireless<br />arthroscopic/endoscopic surgery freeing them from the cables of traditional wired camera systems. The novel Meridian light engine, wireless technology and light weight rechargeable battery are the innovative IP that makes the ArthroFree system possible. The beam from a cold laser directed at a volumetric phosphorus disk emits a bright cool light. An encrypted wireless technology communicates solely between the ArthroFree camera antenna and receiver with no interference to any other OR equipment.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get a glimpse into where its headed.For Lazurite’s inaugural device, the necessity of safety served as the mother of invention. While observing a surgery in 2015, CEO and Cofounder Eugene Malinskiy watched helplessly as a physician’s assistant tripped and fell over cables connected to the surgical tower. The accident drew Eugene’s attention to two cables in particular: the light and power cables that connected at one end to the surgical tower, snaked across the patient into the sterile field, and connected at the other end to thesurgical camera.The ArthroFree wireless surgical camera system allows surgeons to perform wirelessarthroscopic/endoscopic surgery freeing them from the cables of traditional wired camera systems. The novel Meridian light engine, wireless technology and light weight rechargeable battery are the innovative IP that makes the ArthroFree system possible. The beam from a cold laser directed at a volumetric phosphorus disk emits a bright cool light. An encrypted wireless technology communicates solely between the ArthroFree camera antenna and receiver with no interference to any other OR equipment.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Lazurite: The Medical Device Company Turning the OR Wireless (219)]]>
                </itunes:title>
                                    <itunes:episode>19</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get a glimpse into where its headed.<br /><br />For Lazurite’s inaugural device, the necessity of safety served as the mother of invention. While observing a surgery in 2015, CEO and Cofounder Eugene Malinskiy watched helplessly as a physician’s assistant tripped and fell over cables connected to the surgical tower. The accident drew Eugene’s attention to two cables in particular: the light and power cables that connected at one end to the surgical tower, snaked across the patient into the sterile field, and connected at the other end to the<br />surgical camera.<br /><br />The ArthroFree wireless surgical camera system allows surgeons to perform wireless<br />arthroscopic/endoscopic surgery freeing them from the cables of traditional wired camera systems. The novel Meridian light engine, wireless technology and light weight rechargeable battery are the innovative IP that makes the ArthroFree system possible. The beam from a cold laser directed at a volumetric phosphorus disk emits a bright cool light. An encrypted wireless technology communicates solely between the ArthroFree camera antenna and receiver with no interference to any other OR equipment.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702576/c1e-n5mzxi511j6t903qz-8m778n1mb0z5-j2nksq.mp3" length="27887152"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get a glimpse into where its headed.For Lazurite’s inaugural device, the necessity of safety served as the mother of invention. While observing a surgery in 2015, CEO and Cofounder Eugene Malinskiy watched helplessly as a physician’s assistant tripped and fell over cables connected to the surgical tower. The accident drew Eugene’s attention to two cables in particular: the light and power cables that connected at one end to the surgical tower, snaked across the patient into the sterile field, and connected at the other end to thesurgical camera.The ArthroFree wireless surgical camera system allows surgeons to perform wirelessarthroscopic/endoscopic surgery freeing them from the cables of traditional wired camera systems. The novel Meridian light engine, wireless technology and light weight rechargeable battery are the innovative IP that makes the ArthroFree system possible. The beam from a cold laser directed at a volumetric phosphorus disk emits a bright cool light. An encrypted wireless technology communicates solely between the ArthroFree camera antenna and receiver with no interference to any other OR equipment.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702576/c1a-3q87p-xmppk01mb1z2-aar9hd.jpg"></itunes:image>
                                                                            <itunes:duration>00:38:42</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Tommy Barletta: Governmental Affairs Advisor to Startups (218)]]>
                </title>
                <pubDate>Sun, 29 May 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10702721</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/tommy-barletta-governmental-affairs-advisor-to-startups-218-1</link>
                                <description>
                                            <![CDATA[<p>Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more than two decades of experience in Washington and deep Wall Street relationships. This differentiator allows Jones Point to successfully address the disconnect between companies seeking to navigate the regulatory landscape, the Washington lobbying community and investors seeking deeper political insights.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more than two decades of experience in Washington and deep Wall Street relationships. This differentiator allows Jones Point to successfully address the disconnect between companies seeking to navigate the regulatory landscape, the Washington lobbying community and investors seeking deeper political insights.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Tommy Barletta: Governmental Affairs Advisor to Startups (218)]]>
                </itunes:title>
                                    <itunes:episode>18</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more than two decades of experience in Washington and deep Wall Street relationships. This differentiator allows Jones Point to successfully address the disconnect between companies seeking to navigate the regulatory landscape, the Washington lobbying community and investors seeking deeper political insights.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702577/c1e-p51x3i500r6smnq9r-5rvvq9nzu7kj-zzfhfw.mp3" length="17580382"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Mr. Barletta is the founder of an advisory firm based in Washington DC called Jones Point. The firm possesses a unique combination of more than two decades of experience in Washington and deep Wall Street relationships. This differentiator allows Jones Point to successfully address the disconnect between companies seeking to navigate the regulatory landscape, the Washington lobbying community and investors seeking deeper political insights.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702577/c1a-3q87p-mq33975kumwm-fjpu8u.jpg"></itunes:image>
                                                                            <itunes:duration>00:24:23</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[ParaNano: Applying nano technology to wound care (216)]]>
                </title>
                <pubDate>Tue, 24 May 2022 21:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10675804</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/paranano-applying-nano-technology-to-wound-care-216-1</link>
                                <description>
                                            <![CDATA[<p>ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds currently drives $27 billion of cost into the U.S. health care system , and comprises 3% of health care costs in developed countries, globally. PWC was founded in 2018 with the goal to develop and commercialize a truly smart wound care product that would detect and treat infection in a wound. Through market research and customer discovery, PWC decided to develop and commercialize the biosensor portion of this product first as it has an easier FDA pathway and can act as a predict device for planned future product lines. To date, feasibility has been proven and final design prototyping is taking place. PWC has all necessary strategic partners in place for regulatory clearance (both FDA &amp; CMS) and successful distribution/market entry. The company’s initial focus is on wounds treated in Long Term Care (LTC) facilities, then expanding into managed wound care clinics for outpatients. At least 2.5 million seniors in LTC facilities may require chronic wound care in a single year . A high percentage of seniors suffer wounds while in care, often a pressure injury. Care for these patients with wounds in LTC facilities falls largely on the shoulders of inexperienced and minimally trained care takers, resulting in higher rates of infection from late detection of an onset of infection. This leads to higher rates of hospital admittance, expensive treatment plans, and prolonged patient suffering, totaling billions of dollars of wasted resources. Reportedly, chronic, non-healing wounds impact nearly 15% of Medicare beneficiaries each year — or 8.2 million seniors. In other words, wound care costs around $3,000 to $4,000 per incident, per patient . ParaNano Wound Care provides a product that will enable these essential healthcare workers in LTC facilities to properly and timely detect infection, regardless of skill or education level, decreasing the timeline of infection treatment, decreasing hospital admittance, lowering cost, and improving patient outcomes. </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds currently drives $27 billion of cost into the U.S. health care system , and comprises 3% of health care costs in developed countries, globally. PWC was founded in 2018 with the goal to develop and commercialize a truly smart wound care product that would detect and treat infection in a wound. Through market research and customer discovery, PWC decided to develop and commercialize the biosensor portion of this product first as it has an easier FDA pathway and can act as a predict device for planned future product lines. To date, feasibility has been proven and final design prototyping is taking place. PWC has all necessary strategic partners in place for regulatory clearance (both FDA & CMS) and successful distribution/market entry. The company’s initial focus is on wounds treated in Long Term Care (LTC) facilities, then expanding into managed wound care clinics for outpatients. At least 2.5 million seniors in LTC facilities may require chronic wound care in a single year . A high percentage of seniors suffer wounds while in care, often a pressure injury. Care for these patients with wounds in LTC facilities falls largely on the shoulders of inexperienced and minimally trained care takers, resulting in higher rates of infection from late detection of an onset of infection. This leads to higher rates of hospital admittance, expensive treatment plans, and prolonged patient suffering, totaling billions of dollars of wasted resources. Reportedly, chronic, non-healing wounds impact nearly 15% of Medicare beneficiaries each year — or 8.2 million seniors. In other words, wound care costs around $3,000 to $4,000 per incident, per patient . ParaNano Wound Care provides a product that will enable these essential healthcare workers in LTC facilities to properly and timely detect infection, regardless of skill or education level, decreasing the timeline of infection treatment, decreasing hospital admittance, lowering cost, and improving patient outcomes. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[ParaNano: Applying nano technology to wound care (216)]]>
                </itunes:title>
                                    <itunes:episode>16</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds currently drives $27 billion of cost into the U.S. health care system , and comprises 3% of health care costs in developed countries, globally. PWC was founded in 2018 with the goal to develop and commercialize a truly smart wound care product that would detect and treat infection in a wound. Through market research and customer discovery, PWC decided to develop and commercialize the biosensor portion of this product first as it has an easier FDA pathway and can act as a predict device for planned future product lines. To date, feasibility has been proven and final design prototyping is taking place. PWC has all necessary strategic partners in place for regulatory clearance (both FDA &amp; CMS) and successful distribution/market entry. The company’s initial focus is on wounds treated in Long Term Care (LTC) facilities, then expanding into managed wound care clinics for outpatients. At least 2.5 million seniors in LTC facilities may require chronic wound care in a single year . A high percentage of seniors suffer wounds while in care, often a pressure injury. Care for these patients with wounds in LTC facilities falls largely on the shoulders of inexperienced and minimally trained care takers, resulting in higher rates of infection from late detection of an onset of infection. This leads to higher rates of hospital admittance, expensive treatment plans, and prolonged patient suffering, totaling billions of dollars of wasted resources. Reportedly, chronic, non-healing wounds impact nearly 15% of Medicare beneficiaries each year — or 8.2 million seniors. In other words, wound care costs around $3,000 to $4,000 per incident, per patient . ParaNano Wound Care provides a product that will enable these essential healthcare workers in LTC facilities to properly and timely detect infection, regardless of skill or education level, decreasing the timeline of infection treatment, decreasing hospital admittance, lowering cost, and improving patient outcomes. </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702579/c1e-w5k81irzz0mf03w52-qxnnp730fxod-t6bgwi.mp3" length="17720854"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds currently drives $27 billion of cost into the U.S. health care system , and comprises 3% of health care costs in developed countries, globally. PWC was founded in 2018 with the goal to develop and commercialize a truly smart wound care product that would detect and treat infection in a wound. Through market research and customer discovery, PWC decided to develop and commercialize the biosensor portion of this product first as it has an easier FDA pathway and can act as a predict device for planned future product lines. To date, feasibility has been proven and final design prototyping is taking place. PWC has all necessary strategic partners in place for regulatory clearance (both FDA & CMS) and successful distribution/market entry. The company’s initial focus is on wounds treated in Long Term Care (LTC) facilities, then expanding into managed wound care clinics for outpatients. At least 2.5 million seniors in LTC facilities may require chronic wound care in a single year . A high percentage of seniors suffer wounds while in care, often a pressure injury. Care for these patients with wounds in LTC facilities falls largely on the shoulders of inexperienced and minimally trained care takers, resulting in higher rates of infection from late detection of an onset of infection. This leads to higher rates of hospital admittance, expensive treatment plans, and prolonged patient suffering, totaling billions of dollars of wasted resources. Reportedly, chronic, non-healing wounds impact nearly 15% of Medicare beneficiaries each year — or 8.2 million seniors. In other words, wound care costs around $3,000 to $4,000 per incident, per patient . ParaNano Wound Care provides a product that will enable these essential healthcare workers in LTC facilities to properly and timely detect infection, regardless of skill or education level, decreasing the timeline of infection treatment, decreasing hospital admittance, lowering cost, and improving patient outcomes. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702579/c1a-3q87p-xmppk01xir41-pt9hju.jpg"></itunes:image>
                                                                            <itunes:duration>00:24:35</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[DelNova: Addressing complications from Botox (217)]]>
                </title>
                <pubDate>Tue, 24 May 2022 21:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10675886</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/delnova-addressing-complications-from-botox-217-1</link>
                                <description>
                                            <![CDATA[<p>DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[DelNova: Addressing complications from Botox (217)]]>
                </itunes:title>
                                    <itunes:episode>17</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702578/c1e-g0xz8i3wwk1t259wx-jkwwx78vbmno-k9g0cg.mp3" length="13741744"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702578/c1a-3q87p-5rvvq9nzu071-s4zonz.jpg"></itunes:image>
                                                                            <itunes:duration>00:19:03</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[CadexGenomics: Taking the Fight to Stage 4 Cancer (215)]]>
                </title>
                <pubDate>Sat, 21 May 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10658693</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/cadexgenomics-taking-the-fight-to-stage-4-cancer-215-1</link>
                                <description>
                                            <![CDATA[<p>The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. <br /><br />Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me. </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[CadexGenomics: Taking the Fight to Stage 4 Cancer (215)]]>
                </itunes:title>
                                    <itunes:episode>15</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. <br /><br />Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me. </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702584/c1e-n5mzxi511rmi906dv-nj99rk7kh1zv-uow1ai.mp3" length="20186901"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702584/c1a-3q87p-4988430qsmxr-cw1vg6.jpg"></itunes:image>
                                                                            <itunes:duration>00:28:00</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[ScriptChain: Applying Artificial Intelligence to Chronic Heart Related Issues (214)]]>
                </title>
                <pubDate>Sat, 21 May 2022 22:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10658587</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/scriptchain-applying-artificial-intelligence-to-chronic-heart-related-issues-214-1</link>
                                <description>
                                            <![CDATA[<p>ScriptChain is a digital health platform that sits on top of EHR systems and requests patient medical data from the EHR, runs through the platform's algorithms and identifies high risk patient for physicians seeing outpatients with actionable insights. </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[ScriptChain is a digital health platform that sits on top of EHR systems and requests patient medical data from the EHR, runs through the platform's algorithms and identifies high risk patient for physicians seeing outpatients with actionable insights. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[ScriptChain: Applying Artificial Intelligence to Chronic Heart Related Issues (214)]]>
                </itunes:title>
                                    <itunes:episode>14</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>ScriptChain is a digital health platform that sits on top of EHR systems and requests patient medical data from the EHR, runs through the platform's algorithms and identifies high risk patient for physicians seeing outpatients with actionable insights. </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702580/c1e-g0xz8i3wwkku253wv-rommgj9nav6q-oyrs0c.mp3" length="13638916"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[ScriptChain is a digital health platform that sits on top of EHR systems and requests patient medical data from the EHR, runs through the platform's algorithms and identifies high risk patient for physicians seeing outpatients with actionable insights. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702580/c1a-3q87p-xmppk01jtr0n-y0didz.jpg"></itunes:image>
                                                                            <itunes:duration>00:18:54</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Getting Why Right: Colorado Medical Society (213)]]>
                </title>
                <pubDate>Wed, 18 May 2022 06:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10638161</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/getting-why-right-colorado-medical-society-213-1</link>
                                <description>
                                            <![CDATA[<p>Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can it best serve its physician members? Bryan comes to this role after having started his career in broadcasting and later moving into medical society leadership. Now emerging from the pandemic lockdowns, and still addressing clinician burnout and stress, Bryan is leading a number of new initiatives to serve and expand CMS, setting an example for societies all across the US.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can it best serve its physician members? Bryan comes to this role after having started his career in broadcasting and later moving into medical society leadership. Now emerging from the pandemic lockdowns, and still addressing clinician burnout and stress, Bryan is leading a number of new initiatives to serve and expand CMS, setting an example for societies all across the US.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Getting Why Right: Colorado Medical Society (213)]]>
                </itunes:title>
                                    <itunes:episode>13</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can it best serve its physician members? Bryan comes to this role after having started his career in broadcasting and later moving into medical society leadership. Now emerging from the pandemic lockdowns, and still addressing clinician burnout and stress, Bryan is leading a number of new initiatives to serve and expand CMS, setting an example for societies all across the US.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702581/c1e-9pdqoinqqx8idk5kn-4988430qs498-f5xhro.mp3" length="19883329"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can it best serve its physician members? Bryan comes to this role after having started his career in broadcasting and later moving into medical society leadership. Now emerging from the pandemic lockdowns, and still addressing clinician burnout and stress, Bryan is leading a number of new initiatives to serve and expand CMS, setting an example for societies all across the US.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702581/c1a-3q87p-8m778n1gtdo9-sgdkqp.jpg"></itunes:image>
                                                                            <itunes:duration>00:27:35</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Fluo Labs: The Future of Allergy Relief (212)]]>
                </title>
                <pubDate>Sat, 14 May 2022 22:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10617690</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/fluo-labs-the-future-of-allergy-relief-212-1</link>
                                <description>
                                            <![CDATA[<p>Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever) symptoms. They are inventing a whole new way for sufferers of seasonal allergies to get symptom relief, and ultimately improve their quality of life. The Fluo device is designed to use light therapy to reduce inflammation and temporarily alleviate allergy symptoms as a completely drug-free alternative to common allergy medications.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever) symptoms. They are inventing a whole new way for sufferers of seasonal allergies to get symptom relief, and ultimately improve their quality of life. The Fluo device is designed to use light therapy to reduce inflammation and temporarily alleviate allergy symptoms as a completely drug-free alternative to common allergy medications.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Fluo Labs: The Future of Allergy Relief (212)]]>
                </itunes:title>
                                    <itunes:episode>12</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever) symptoms. They are inventing a whole new way for sufferers of seasonal allergies to get symptom relief, and ultimately improve their quality of life. The Fluo device is designed to use light therapy to reduce inflammation and temporarily alleviate allergy symptoms as a completely drug-free alternative to common allergy medications.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702582/c1e-3q87pt5004zakx2k5-8m778n1puzkw-bnupm5.mp3" length="18032538"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever) symptoms. They are inventing a whole new way for sufferers of seasonal allergies to get symptom relief, and ultimately improve their quality of life. The Fluo device is designed to use light therapy to reduce inflammation and temporarily alleviate allergy symptoms as a completely drug-free alternative to common allergy medications.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702582/c1a-3q87p-jkwwx78vb7nm-dncixv.jpg"></itunes:image>
                                                                            <itunes:duration>00:25:00</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[ConveyMed: The podcasting app for medical professionals (211)]]>
                </title>
                <pubDate>Sat, 14 May 2022 22:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10617686</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/conveymed-the-podcasting-app-for-medical-professionals-211-1</link>
                                <description>
                                            <![CDATA[<p>ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education.  Busy physicians, nurses, pharmacists and other professionals want the convenience of a mobile audio platform to complete their annual continuing education requirements but open platforms like Apple Podcasts and Spotify cannot fulfill this purpose. The Convey mission is to elevate podcasting as an educational medium for professional learners, and our goal is to be the premiere mobile education platform for medical professionals. Unlike with Apple or Spotify, busy healthcare professionals can earn their required annual continuing education credits while listening to a podcast on ConveyMED instead of attending a conference or logging in to a late-night webinar. ConveyMED is a digital marketplace offering revenue-sharing partnerships with content providers such as professional associations, academic medical centers, and other CME providers.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education.  Busy physicians, nurses, pharmacists and other professionals want the convenience of a mobile audio platform to complete their annual continuing education requirements but open platforms like Apple Podcasts and Spotify cannot fulfill this purpose. The Convey mission is to elevate podcasting as an educational medium for professional learners, and our goal is to be the premiere mobile education platform for medical professionals. Unlike with Apple or Spotify, busy healthcare professionals can earn their required annual continuing education credits while listening to a podcast on ConveyMED instead of attending a conference or logging in to a late-night webinar. ConveyMED is a digital marketplace offering revenue-sharing partnerships with content providers such as professional associations, academic medical centers, and other CME providers.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[ConveyMed: The podcasting app for medical professionals (211)]]>
                </itunes:title>
                                    <itunes:episode>11</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education.  Busy physicians, nurses, pharmacists and other professionals want the convenience of a mobile audio platform to complete their annual continuing education requirements but open platforms like Apple Podcasts and Spotify cannot fulfill this purpose. The Convey mission is to elevate podcasting as an educational medium for professional learners, and our goal is to be the premiere mobile education platform for medical professionals. Unlike with Apple or Spotify, busy healthcare professionals can earn their required annual continuing education credits while listening to a podcast on ConveyMED instead of attending a conference or logging in to a late-night webinar. ConveyMED is a digital marketplace offering revenue-sharing partnerships with content providers such as professional associations, academic medical centers, and other CME providers.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702585/c1e-2pz4vi80039a6903p-dd77j80rbr92-bjbyrw.mp3" length="19206426"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education.  Busy physicians, nurses, pharmacists and other professionals want the convenience of a mobile audio platform to complete their annual continuing education requirements but open platforms like Apple Podcasts and Spotify cannot fulfill this purpose. The Convey mission is to elevate podcasting as an educational medium for professional learners, and our goal is to be the premiere mobile education platform for medical professionals. Unlike with Apple or Spotify, busy healthcare professionals can earn their required annual continuing education credits while listening to a podcast on ConveyMED instead of attending a conference or logging in to a late-night webinar. ConveyMED is a digital marketplace offering revenue-sharing partnerships with content providers such as professional associations, academic medical centers, and other CME providers.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702585/c1a-3q87p-8m778n1nfz8-x8vphb.jpg"></itunes:image>
                                                                            <itunes:duration>00:26:38</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Triple Threat - Clinician, Researcher & Teacher: Ian Sarembock, MD (210)]]>
                </title>
                <pubDate>Fri, 15 Apr 2022 18:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10445679</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/triple-threat-clinician-researcher-teacher-ian-sarembock-md-210-1</link>
                                <description>
                                            <![CDATA[<p>Ian Sarembock, MD - is a retired Coronary &amp; Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at The Christ Hospital in Cincinnati, OH. <br /><br />His work spanned Interventional Cardiology, Valve &amp; Structural Heart, Cardiology, Clinical Research, and Medical Education. He earned his Doctor of Medicine (MD) focused in Cardiovascular Science from University of Cape Town.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at The Christ Hospital in Cincinnati, OH. His work spanned Interventional Cardiology, Valve & Structural Heart, Cardiology, Clinical Research, and Medical Education. He earned his Doctor of Medicine (MD) focused in Cardiovascular Science from University of Cape Town.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Triple Threat - Clinician, Researcher & Teacher: Ian Sarembock, MD (210)]]>
                </itunes:title>
                                    <itunes:episode>10</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Ian Sarembock, MD - is a retired Coronary &amp; Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at The Christ Hospital in Cincinnati, OH. <br /><br />His work spanned Interventional Cardiology, Valve &amp; Structural Heart, Cardiology, Clinical Research, and Medical Education. He earned his Doctor of Medicine (MD) focused in Cardiovascular Science from University of Cape Town.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702583/c1e-odgzobv00k6c8p2ok-qxnnp732h3ox-iaaadv.mp3" length="33863491"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at The Christ Hospital in Cincinnati, OH. His work spanned Interventional Cardiology, Valve & Structural Heart, Cardiology, Clinical Research, and Medical Education. He earned his Doctor of Medicine (MD) focused in Cardiovascular Science from University of Cape Town.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702583/c1a-3q87p-v088v9m3szx8-fnmlpe.jpg"></itunes:image>
                                                                            <itunes:duration>00:47:00</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[John Pigott, MD FACS - Surgeon, Entrepreneur, Head of Innovation - Promedica (209)]]>
                </title>
                <pubDate>Thu, 10 Mar 2022 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10229060</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/john-pigott-md-facs-surgeon-entrepreneur-head-of-innovation-promedica-209-1</link>
                                <description>
                                            <![CDATA[<p>John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders from across the health system to turn ideas into results that generate a measurable impact in the areas of life science technologies, patient outcomes, and new revenue streams. He is also a member of ProMedica’s executive strategy team. Dr. Pigott has designed, developed and implemented recognized and award-winning medical innovations, specifically within the field of vascular surgery. He is the founder and Chief Science Officer for VentureMed Group and Infinity Angioplasty Balloon company, both medical device companies involved in the treatment of peripheral artery disease. He is the author of many articles and presentations, and holds numerous patents, primarily in the life sciences field.</p><p>Dr. Pigott is President of the Northwest Ohio Tech Fund II, a Board of Trustees Member for BioOhio, and a Board member of Kapios Health. He is also a former EY Regional Award and National Finalist for Entrepreneur of the Year, a national and international venture capitalist, and a lead developer in establishing the Northwest Ohio ESP and Tech Fund II through the State of Ohio Third Frontier. He has helped to attract more than $50 million to Northwest Ohio, resulting in local job creation and economic development. He also serves as a consultant to numerous multinational medical device companies, conducts national and regional device training programs, and has participated in more than 50 clinical trials.</p><p>As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. He is also a clinical professor of surgery at the University of Toledo Medical Center. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his surgical residency at Akron City Hospital, and completed his fellowship in vascular surgery at the Mayo Clinic.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders from across the health system to turn ideas into results that generate a measurable impact in the areas of life science technologies, patient outcomes, and new revenue streams. He is also a member of ProMedica’s executive strategy team. Dr. Pigott has designed, developed and implemented recognized and award-winning medical innovations, specifically within the field of vascular surgery. He is the founder and Chief Science Officer for VentureMed Group and Infinity Angioplasty Balloon company, both medical device companies involved in the treatment of peripheral artery disease. He is the author of many articles and presentations, and holds numerous patents, primarily in the life sciences field.Dr. Pigott is President of the Northwest Ohio Tech Fund II, a Board of Trustees Member for BioOhio, and a Board member of Kapios Health. He is also a former EY Regional Award and National Finalist for Entrepreneur of the Year, a national and international venture capitalist, and a lead developer in establishing the Northwest Ohio ESP and Tech Fund II through the State of Ohio Third Frontier. He has helped to attract more than $50 million to Northwest Ohio, resulting in local job creation and economic development. He also serves as a consultant to numerous multinational medical device companies, conducts national and regional device training programs, and has participated in more than 50 clinical trials.As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. He is also a clinical professor of surgery at the University of Toledo Medical Center. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his surgical residency at Akron City Hospital, and completed his fellowship in vascular surgery at the Mayo Clinic.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[John Pigott, MD FACS - Surgeon, Entrepreneur, Head of Innovation - Promedica (209)]]>
                </itunes:title>
                                    <itunes:episode>9</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders from across the health system to turn ideas into results that generate a measurable impact in the areas of life science technologies, patient outcomes, and new revenue streams. He is also a member of ProMedica’s executive strategy team. Dr. Pigott has designed, developed and implemented recognized and award-winning medical innovations, specifically within the field of vascular surgery. He is the founder and Chief Science Officer for VentureMed Group and Infinity Angioplasty Balloon company, both medical device companies involved in the treatment of peripheral artery disease. He is the author of many articles and presentations, and holds numerous patents, primarily in the life sciences field.</p><p>Dr. Pigott is President of the Northwest Ohio Tech Fund II, a Board of Trustees Member for BioOhio, and a Board member of Kapios Health. He is also a former EY Regional Award and National Finalist for Entrepreneur of the Year, a national and international venture capitalist, and a lead developer in establishing the Northwest Ohio ESP and Tech Fund II through the State of Ohio Third Frontier. He has helped to attract more than $50 million to Northwest Ohio, resulting in local job creation and economic development. He also serves as a consultant to numerous multinational medical device companies, conducts national and regional device training programs, and has participated in more than 50 clinical trials.</p><p>As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. He is also a clinical professor of surgery at the University of Toledo Medical Center. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his surgical residency at Akron City Hospital, and completed his fellowship in vascular surgery at the Mayo Clinic.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702586/c1e-r583rijmm1ns2xpk4-qxnnp73qb756-3mj2tz.mp3" length="22726766"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders from across the health system to turn ideas into results that generate a measurable impact in the areas of life science technologies, patient outcomes, and new revenue streams. He is also a member of ProMedica’s executive strategy team. Dr. Pigott has designed, developed and implemented recognized and award-winning medical innovations, specifically within the field of vascular surgery. He is the founder and Chief Science Officer for VentureMed Group and Infinity Angioplasty Balloon company, both medical device companies involved in the treatment of peripheral artery disease. He is the author of many articles and presentations, and holds numerous patents, primarily in the life sciences field.Dr. Pigott is President of the Northwest Ohio Tech Fund II, a Board of Trustees Member for BioOhio, and a Board member of Kapios Health. He is also a former EY Regional Award and National Finalist for Entrepreneur of the Year, a national and international venture capitalist, and a lead developer in establishing the Northwest Ohio ESP and Tech Fund II through the State of Ohio Third Frontier. He has helped to attract more than $50 million to Northwest Ohio, resulting in local job creation and economic development. He also serves as a consultant to numerous multinational medical device companies, conducts national and regional device training programs, and has participated in more than 50 clinical trials.As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. He is also a clinical professor of surgery at the University of Toledo Medical Center. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his surgical residency at Akron City Hospital, and completed his fellowship in vascular surgery at the Mayo Clinic.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702586/c1a-3q87p-o8rr02x2fmz-s5oozn.jpg"></itunes:image>
                                                                            <itunes:duration>00:31:32</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[David Yakobi, MD - Insights On Serving as a Physician Advisor to Startups (208)]]>
                </title>
                <pubDate>Tue, 08 Mar 2022 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10211437</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/david-yakobi-md-insights-on-serving-as-a-physician-advisor-to-startups-208-1</link>
                                <description>
                                            <![CDATA[<p>David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast experience in Coronary Artery Disease (CAD), Valvular disease, and Pediatric congenital heart disease. <br /><br />He also plays a key role as a medical consultant to major startup companies in the healthcare industry with particular emphasis on medical devices and digital-health. </p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast experience in Coronary Artery Disease (CAD), Valvular disease, and Pediatric congenital heart disease. He also plays a key role as a medical consultant to major startup companies in the healthcare industry with particular emphasis on medical devices and digital-health. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[David Yakobi, MD - Insights On Serving as a Physician Advisor to Startups (208)]]>
                </itunes:title>
                                    <itunes:episode>8</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast experience in Coronary Artery Disease (CAD), Valvular disease, and Pediatric congenital heart disease. <br /><br />He also plays a key role as a medical consultant to major startup companies in the healthcare industry with particular emphasis on medical devices and digital-health. </p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702587/c1e-m2njdun33g3hwvdxj-wnvv4r2qikq8-eitvnt.mp3" length="24540882"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast experience in Coronary Artery Disease (CAD), Valvular disease, and Pediatric congenital heart disease. He also plays a key role as a medical consultant to major startup companies in the healthcare industry with particular emphasis on medical devices and digital-health. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702587/c1a-3q87p-mq339756ippj-btqv8c.jpg"></itunes:image>
                                                                            <itunes:duration>00:34:03</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Saralyn Mark, MD - Human centered design on Earth and in Space (207)]]>
                </title>
                <pubDate>Tue, 01 Mar 2022 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10171889</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/saralyn-mark-md-human-centered-design-on-earth-and-in-space-207-1</link>
                                <description>
                                            <![CDATA[<p>Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services. She designed the first women’s health fellowship in the US, helped create the National Centers of Leadership in Academic Medicine, the National Centers of Excellence in Women’s Health, and landmark educational campaigns on critical health issues. She has published and delivered over 600 lectures and is a frequent health media expert. Dr. Mark works with agencies, academia, industry and NGOs around the globe. As President of SolaMed Solutions, LLC, Dr. Mark serves as a medical and scientific policy advisor to the White House, NASA and other organizations dedicated to improving health on Earth and in space. She holds 4 academic appointments including at Yale and Kings College-London. She is author of Stellar Medicine: A Journey Through the Universe of Women's Health.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services. She designed the first women’s health fellowship in the US, helped create the National Centers of Leadership in Academic Medicine, the National Centers of Excellence in Women’s Health, and landmark educational campaigns on critical health issues. She has published and delivered over 600 lectures and is a frequent health media expert. Dr. Mark works with agencies, academia, industry and NGOs around the globe. As President of SolaMed Solutions, LLC, Dr. Mark serves as a medical and scientific policy advisor to the White House, NASA and other organizations dedicated to improving health on Earth and in space. She holds 4 academic appointments including at Yale and Kings College-London. She is author of Stellar Medicine: A Journey Through the Universe of Women's Health.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Saralyn Mark, MD - Human centered design on Earth and in Space (207)]]>
                </itunes:title>
                                    <itunes:episode>7</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services. She designed the first women’s health fellowship in the US, helped create the National Centers of Leadership in Academic Medicine, the National Centers of Excellence in Women’s Health, and landmark educational campaigns on critical health issues. She has published and delivered over 600 lectures and is a frequent health media expert. Dr. Mark works with agencies, academia, industry and NGOs around the globe. As President of SolaMed Solutions, LLC, Dr. Mark serves as a medical and scientific policy advisor to the White House, NASA and other organizations dedicated to improving health on Earth and in space. She holds 4 academic appointments including at Yale and Kings College-London. She is author of Stellar Medicine: A Journey Through the Universe of Women's Health.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702588/c1e-q2zo9u2pp04f0or73-5rvvq9nwbpo9-guccek.mp3" length="22982166"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services. She designed the first women’s health fellowship in the US, helped create the National Centers of Leadership in Academic Medicine, the National Centers of Excellence in Women’s Health, and landmark educational campaigns on critical health issues. She has published and delivered over 600 lectures and is a frequent health media expert. Dr. Mark works with agencies, academia, industry and NGOs around the globe. As President of SolaMed Solutions, LLC, Dr. Mark serves as a medical and scientific policy advisor to the White House, NASA and other organizations dedicated to improving health on Earth and in space. She holds 4 academic appointments including at Yale and Kings College-London. She is author of Stellar Medicine: A Journey Through the Universe of Women's Health.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702588/c1a-3q87p-dd77j800tnog-k6u9ud.jpg"></itunes:image>
                                                                            <itunes:duration>00:31:53</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Michael Meighen, MD - Holistic medicine and life (206)]]>
                </title>
                <pubDate>Wed, 23 Feb 2022 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10126903</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/michael-meighen-md-holistic-medicine-and-life-206-1</link>
                                <description>
                                            <![CDATA[<p>Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book "A New You: Using the Body's Regenerative and Restorative Healing Powers to Optimize Orthopedic, Hormonal, and Sexual Health Function". He is a specialist in musculoskeletal and health transformation as well as longevity and restorative medicine. His practice and approach to medicine is both proactive and practical with the goal of helping patients optimize health. He practices in Florida and you can reach him through his practice website: www.livelimitlessmd.com.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book "A New You: Using the Body's Regenerative and Restorative Healing Powers to Optimize Orthopedic, Hormonal, and Sexual Health Function". He is a specialist in musculoskeletal and health transformation as well as longevity and restorative medicine. His practice and approach to medicine is both proactive and practical with the goal of helping patients optimize health. He practices in Florida and you can reach him through his practice website: www.livelimitlessmd.com.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Michael Meighen, MD - Holistic medicine and life (206)]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book "A New You: Using the Body's Regenerative and Restorative Healing Powers to Optimize Orthopedic, Hormonal, and Sexual Health Function". He is a specialist in musculoskeletal and health transformation as well as longevity and restorative medicine. His practice and approach to medicine is both proactive and practical with the goal of helping patients optimize health. He practices in Florida and you can reach him through his practice website: www.livelimitlessmd.com.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702589/c1e-jg935sq11dqcnzw41-8m778n13cdmo-z493iw.mp3" length="30616626"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book "A New You: Using the Body's Regenerative and Restorative Healing Powers to Optimize Orthopedic, Hormonal, and Sexual Health Function". He is a specialist in musculoskeletal and health transformation as well as longevity and restorative medicine. His practice and approach to medicine is both proactive and practical with the goal of helping patients optimize health. He practices in Florida and you can reach him through his practice website: www.livelimitlessmd.com.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702589/c1a-3q87p-jkwwx788co4k-0qv6ew.jpg"></itunes:image>
                                                                            <itunes:duration>00:42:29</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Jaffar Raza, MD - Opportunities, Cost Management and Technology (205)]]>
                </title>
                <pubDate>Wed, 09 Feb 2022 13:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-10042262</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/jaffar-raza-md-opportunities-cost-management-and-technology-205-1</link>
                                <description>
                                            <![CDATA[<p>Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal Medicine at United Health Services Hospitals and his Geriatrics and Cardiovascular fellowship at East Carolina University. He completed his fellowship in Interventional Cardiology and Peripheral Intervention at Lenox Hill Hospital. Dr. Raza’s interests include complex coronary interventions, radial access, peripheral interventions, nuclear cardiology, and echocardiography. Dr. Raza has published numerous articles in well-known medical journals and is active in teaching residents and fellows and is a member of the AngelMD Clinical Advisory Board.</p><p>He is board certified in Nuclear Cardiology, Cardiovascular Disease, and Interventional Cardiology. He is a member of the American College of Cardiology and the Society of Coronary Angiography and Intervention.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal Medicine at United Health Services Hospitals and his Geriatrics and Cardiovascular fellowship at East Carolina University. He completed his fellowship in Interventional Cardiology and Peripheral Intervention at Lenox Hill Hospital. Dr. Raza’s interests include complex coronary interventions, radial access, peripheral interventions, nuclear cardiology, and echocardiography. Dr. Raza has published numerous articles in well-known medical journals and is active in teaching residents and fellows and is a member of the AngelMD Clinical Advisory Board.He is board certified in Nuclear Cardiology, Cardiovascular Disease, and Interventional Cardiology. He is a member of the American College of Cardiology and the Society of Coronary Angiography and Intervention.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Jaffar Raza, MD - Opportunities, Cost Management and Technology (205)]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal Medicine at United Health Services Hospitals and his Geriatrics and Cardiovascular fellowship at East Carolina University. He completed his fellowship in Interventional Cardiology and Peripheral Intervention at Lenox Hill Hospital. Dr. Raza’s interests include complex coronary interventions, radial access, peripheral interventions, nuclear cardiology, and echocardiography. Dr. Raza has published numerous articles in well-known medical journals and is active in teaching residents and fellows and is a member of the AngelMD Clinical Advisory Board.</p><p>He is board certified in Nuclear Cardiology, Cardiovascular Disease, and Interventional Cardiology. He is a member of the American College of Cardiology and the Society of Coronary Angiography and Intervention.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702590/c1e-64532c2wwxohn9oj5-1xgg2v3ji49k-qcpuq8.mp3" length="31639024"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal Medicine at United Health Services Hospitals and his Geriatrics and Cardiovascular fellowship at East Carolina University. He completed his fellowship in Interventional Cardiology and Peripheral Intervention at Lenox Hill Hospital. Dr. Raza’s interests include complex coronary interventions, radial access, peripheral interventions, nuclear cardiology, and echocardiography. Dr. Raza has published numerous articles in well-known medical journals and is active in teaching residents and fellows and is a member of the AngelMD Clinical Advisory Board.He is board certified in Nuclear Cardiology, Cardiovascular Disease, and Interventional Cardiology. He is a member of the American College of Cardiology and the Society of Coronary Angiography and Intervention.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702590/c1a-3q87p-p800n2o3iw79-suhstg.jpg"></itunes:image>
                                                                            <itunes:duration>00:43:54</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[David Finkel Founder/CEO of Maui Mastermind - (Part 3) (204)]]>
                </title>
                <pubDate>Mon, 24 Jan 2022 18:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9942989</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/david-finkel-founderceo-of-maui-mastermind-part-3-204-1</link>
                                <description>
                                            <![CDATA[]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[David Finkel Founder/CEO of Maui Mastermind - (Part 3) (204)]]>
                </itunes:title>
                                    <itunes:episode>4</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702592/c1e-k1r97cjxx98b972m4-7n5580ggskv0-iv8udk.mp3" length="13555647"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702592/c1a-3q87p-p800n2o7bqjr-f2klva.jpg"></itunes:image>
                                                                            <itunes:duration>00:18:47</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Doug Freedberg, MD - Orthopedic Surgeon & Sports Medicine (203)]]>
                </title>
                <pubDate>Mon, 17 Jan 2022 17:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9900953</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/doug-freedberg-md-orthopedic-surgeon-sports-medicine-203-1</link>
                                <description>
                                            <![CDATA[<p>Doug Freedberg, MD is a board-certified orthopedic surgeon (with sports medicine subspecialty certification) specializing in knee and shoulder arthroscopy, ACL reconstruction, sports medicine, golf injuries, injuries to the throwing athlete as well as total knee arthroplasty. He followed his orthopedic residency at the Hospital for Special Surgery in NY, the #1 ranked orthopedic program in the country, with a sports medicine fellowship with world renowned Dr. James Andrews. He is a team orthopedic surgeon for the Arizona Cardinals and a consultant with the Oakland Athletics. He also serves on the AngelMD Clinical Advisory Board as co-Chairman of Orthopedics.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Doug Freedberg, MD is a board-certified orthopedic surgeon (with sports medicine subspecialty certification) specializing in knee and shoulder arthroscopy, ACL reconstruction, sports medicine, golf injuries, injuries to the throwing athlete as well as total knee arthroplasty. He followed his orthopedic residency at the Hospital for Special Surgery in NY, the #1 ranked orthopedic program in the country, with a sports medicine fellowship with world renowned Dr. James Andrews. He is a team orthopedic surgeon for the Arizona Cardinals and a consultant with the Oakland Athletics. He also serves on the AngelMD Clinical Advisory Board as co-Chairman of Orthopedics.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Doug Freedberg, MD - Orthopedic Surgeon & Sports Medicine (203)]]>
                </itunes:title>
                                    <itunes:episode>3</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Doug Freedberg, MD is a board-certified orthopedic surgeon (with sports medicine subspecialty certification) specializing in knee and shoulder arthroscopy, ACL reconstruction, sports medicine, golf injuries, injuries to the throwing athlete as well as total knee arthroplasty. He followed his orthopedic residency at the Hospital for Special Surgery in NY, the #1 ranked orthopedic program in the country, with a sports medicine fellowship with world renowned Dr. James Andrews. He is a team orthopedic surgeon for the Arizona Cardinals and a consultant with the Oakland Athletics. He also serves on the AngelMD Clinical Advisory Board as co-Chairman of Orthopedics.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702593/c1e-d3q2gh6vvgjfpzn53-dd77j809so0j-urs0yr.mp3" length="15777637"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Doug Freedberg, MD is a board-certified orthopedic surgeon (with sports medicine subspecialty certification) specializing in knee and shoulder arthroscopy, ACL reconstruction, sports medicine, golf injuries, injuries to the throwing athlete as well as total knee arthroplasty. He followed his orthopedic residency at the Hospital for Special Surgery in NY, the #1 ranked orthopedic program in the country, with a sports medicine fellowship with world renowned Dr. James Andrews. He is a team orthopedic surgeon for the Arizona Cardinals and a consultant with the Oakland Athletics. He also serves on the AngelMD Clinical Advisory Board as co-Chairman of Orthopedics.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702593/c1a-3q87p-zo771m88fpo3-pdinht.jpg"></itunes:image>
                                                                            <itunes:duration>00:21:53</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[David Finkel Founder/CEO of Maui Mastermind - (Part 2) (202)]]>
                </title>
                <pubDate>Tue, 11 Jan 2022 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9868820</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/david-finkel-founderceo-of-maui-mastermind-part-2-202-1</link>
                                <description>
                                            <![CDATA[]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[David Finkel Founder/CEO of Maui Mastermind - (Part 2) (202)]]>
                </itunes:title>
                                    <itunes:episode>2</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702591/c1e-7w79ds422jvtd8qk6-k5xxoqvvt7vn-qx2wcd.mp3" length="12086416"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702591/c1a-3q87p-60pp8rmgb8gz-uqooau.jpg"></itunes:image>
                                                                            <itunes:duration>00:16:45</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Amir Baluch, MD - Physician Side Hustle & Bio Wise Fund I & II (201)]]>
                </title>
                <pubDate>Mon, 10 Jan 2022 20:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9861967</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/amir-baluch-md-physician-side-hustle-bio-wise-fund-i-ii-201-1</link>
                                <description>
                                            <![CDATA[<p>Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and securities with series 22 and 63, four years experience under a broker-dealer where he trained to evaluate opportunities, negotiate, mitigate risk, and underwrite.</p><p>He is also an internationally best-selling author of the wealth management and investment book “Make It, Keep It – New Age Wealth Strategies for Physicians” and a regular contributor to <em>Forbes</em>. He and his team have participated in or managed over 80 investment projects, valued over $500M.  His recent ventures include educational summits such as the Wealth Strategies Summit and Side Hustle MD. His other ventures include high level e-commerce consulting, real estate development, and growth hacking.</p><p>Dr. Baluch has a degree in Biochemistry from Trinity University and obtained his medical degree from Texas Tech before finishing his anesthesia residency at University of Miami.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and securities with series 22 and 63, four years experience under a broker-dealer where he trained to evaluate opportunities, negotiate, mitigate risk, and underwrite.He is also an internationally best-selling author of the wealth management and investment book “Make It, Keep It – New Age Wealth Strategies for Physicians” and a regular contributor to Forbes. He and his team have participated in or managed over 80 investment projects, valued over $500M.  His recent ventures include educational summits such as the Wealth Strategies Summit and Side Hustle MD. His other ventures include high level e-commerce consulting, real estate development, and growth hacking.Dr. Baluch has a degree in Biochemistry from Trinity University and obtained his medical degree from Texas Tech before finishing his anesthesia residency at University of Miami.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Amir Baluch, MD - Physician Side Hustle & Bio Wise Fund I & II (201)]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                    <itunes:season>2</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and securities with series 22 and 63, four years experience under a broker-dealer where he trained to evaluate opportunities, negotiate, mitigate risk, and underwrite.</p><p>He is also an internationally best-selling author of the wealth management and investment book “Make It, Keep It – New Age Wealth Strategies for Physicians” and a regular contributor to <em>Forbes</em>. He and his team have participated in or managed over 80 investment projects, valued over $500M.  His recent ventures include educational summits such as the Wealth Strategies Summit and Side Hustle MD. His other ventures include high level e-commerce consulting, real estate development, and growth hacking.</p><p>Dr. Baluch has a degree in Biochemistry from Trinity University and obtained his medical degree from Texas Tech before finishing his anesthesia residency at University of Miami.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702594/c1e-52po7umgg9dc0zj62-8m778n1zbvqk-begrfg.mp3" length="11611943"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and securities with series 22 and 63, four years experience under a broker-dealer where he trained to evaluate opportunities, negotiate, mitigate risk, and underwrite.He is also an internationally best-selling author of the wealth management and investment book “Make It, Keep It – New Age Wealth Strategies for Physicians” and a regular contributor to Forbes. He and his team have participated in or managed over 80 investment projects, valued over $500M.  His recent ventures include educational summits such as the Wealth Strategies Summit and Side Hustle MD. His other ventures include high level e-commerce consulting, real estate development, and growth hacking.Dr. Baluch has a degree in Biochemistry from Trinity University and obtained his medical degree from Texas Tech before finishing his anesthesia residency at University of Miami.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702594/c1a-3q87p-jkwwx781h8k-m1czag.jpg"></itunes:image>
                                                                            <itunes:duration>00:16:07</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[David Finkel, Founder/CEO of Maui Mastermind (Part 1) (030)]]>
                </title>
                <pubDate>Wed, 22 Dec 2021 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9763501</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/david-finkel-founderceo-of-maui-mastermind-part-1-030-1</link>
                                <description>
                                            <![CDATA[<p>David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He is a Wall Street Journal bestselling author of eleven books, including SCALE (co-authored with Priceline.com Co-founder Jeff Hoffman) and The Freedom Formula: How to Succeed in Business Without Sacrificing Your Family, Health, or Life. <br /><br />David’s syndicated business articles can be seen on Inc.com, Fastcompany.com, and Forbes.com and have garnered millions of readers and his work has been featured in several prestigious media outlets including the Wall Street Journal, Bloomberg, Fox Business, MSNBC, and Inc. Magazine. <br /><br />He has helped hundreds of thousands of business leaders grow their companies and get their lives back. He lives in Jackson Hole, Wyoming with his wife and three sons and is the son of a physician.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He is a Wall Street Journal bestselling author of eleven books, including SCALE (co-authored with Priceline.com Co-founder Jeff Hoffman) and The Freedom Formula: How to Succeed in Business Without Sacrificing Your Family, Health, or Life. David’s syndicated business articles can be seen on Inc.com, Fastcompany.com, and Forbes.com and have garnered millions of readers and his work has been featured in several prestigious media outlets including the Wall Street Journal, Bloomberg, Fox Business, MSNBC, and Inc. Magazine. He has helped hundreds of thousands of business leaders grow their companies and get their lives back. He lives in Jackson Hole, Wyoming with his wife and three sons and is the son of a physician.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[David Finkel, Founder/CEO of Maui Mastermind (Part 1) (030)]]>
                </itunes:title>
                                    <itunes:episode>30</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He is a Wall Street Journal bestselling author of eleven books, including SCALE (co-authored with Priceline.com Co-founder Jeff Hoffman) and The Freedom Formula: How to Succeed in Business Without Sacrificing Your Family, Health, or Life. <br /><br />David’s syndicated business articles can be seen on Inc.com, Fastcompany.com, and Forbes.com and have garnered millions of readers and his work has been featured in several prestigious media outlets including the Wall Street Journal, Bloomberg, Fox Business, MSNBC, and Inc. Magazine. <br /><br />He has helped hundreds of thousands of business leaders grow their companies and get their lives back. He lives in Jackson Hole, Wyoming with his wife and three sons and is the son of a physician.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702595/c1e-d3q2gh6vvg1hpo38r-33225orpi7pz-cs8hge.mp3" length="10151681"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He is a Wall Street Journal bestselling author of eleven books, including SCALE (co-authored with Priceline.com Co-founder Jeff Hoffman) and The Freedom Formula: How to Succeed in Business Without Sacrificing Your Family, Health, or Life. David’s syndicated business articles can be seen on Inc.com, Fastcompany.com, and Forbes.com and have garnered millions of readers and his work has been featured in several prestigious media outlets including the Wall Street Journal, Bloomberg, Fox Business, MSNBC, and Inc. Magazine. He has helped hundreds of thousands of business leaders grow their companies and get their lives back. He lives in Jackson Hole, Wyoming with his wife and three sons and is the son of a physician.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702595/c1a-3q87p-nj99rk7xs2vw-iqn6m7.jpg"></itunes:image>
                                                                            <itunes:duration>00:14:03</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Transverse Medical (029)]]>
                </title>
                <pubDate>Sun, 19 Dec 2021 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9744983</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/transverse-medical-029-1</link>
                                <description>
                                            <![CDATA[<p>TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex arch anatomy by maintaining contact with the aorta, enabling maximum great arch vessel coverage, and directing debris-laden blood through the filter. Thus, safeguarding the brain to provide complete embolic protection for addressing the unmet clinical need to keep debris out of the cerebral arteries and protect all territories of the brain during left heart procedures. Initial procedure focus is Transcatheter Aortic Valve Replacement (TAVR). During TAVR, procedural stroke is documented as high as 9.1% and clinically-significant debris is present in 99% of patients (SENTINEL Trial, Control Arm Data, JACC, Nov 2016).<br /><br /><a href="https://www.angelmd.co/en/startups/transversemedicalinc"><b>AngelMD Profile</b></a></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex arch anatomy by maintaining contact with the aorta, enabling maximum great arch vessel coverage, and directing debris-laden blood through the filter. Thus, safeguarding the brain to provide complete embolic protection for addressing the unmet clinical need to keep debris out of the cerebral arteries and protect all territories of the brain during left heart procedures. Initial procedure focus is Transcatheter Aortic Valve Replacement (TAVR). During TAVR, procedural stroke is documented as high as 9.1% and clinically-significant debris is present in 99% of patients (SENTINEL Trial, Control Arm Data, JACC, Nov 2016).AngelMD Profile]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Transverse Medical (029)]]>
                </itunes:title>
                                    <itunes:episode>29</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex arch anatomy by maintaining contact with the aorta, enabling maximum great arch vessel coverage, and directing debris-laden blood through the filter. Thus, safeguarding the brain to provide complete embolic protection for addressing the unmet clinical need to keep debris out of the cerebral arteries and protect all territories of the brain during left heart procedures. Initial procedure focus is Transcatheter Aortic Valve Replacement (TAVR). During TAVR, procedural stroke is documented as high as 9.1% and clinically-significant debris is present in 99% of patients (SENTINEL Trial, Control Arm Data, JACC, Nov 2016).<br /><br /><a href="https://www.angelmd.co/en/startups/transversemedicalinc"><b>AngelMD Profile</b></a></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702596/c1e-z6jkvhm55rxaodkwv-jkwwx78mb7j5-ar5bnt.mp3" length="13895839"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex arch anatomy by maintaining contact with the aorta, enabling maximum great arch vessel coverage, and directing debris-laden blood through the filter. Thus, safeguarding the brain to provide complete embolic protection for addressing the unmet clinical need to keep debris out of the cerebral arteries and protect all territories of the brain during left heart procedures. Initial procedure focus is Transcatheter Aortic Valve Replacement (TAVR). During TAVR, procedural stroke is documented as high as 9.1% and clinically-significant debris is present in 99% of patients (SENTINEL Trial, Control Arm Data, JACC, Nov 2016).AngelMD Profile]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702596/c1a-3q87p-1xgg2v36fn80-mrtqvo.jpg"></itunes:image>
                                                                            <itunes:duration>00:19:16</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Physician, Innovator & Advisor - Ramin Rafie, MD (028)]]>
                </title>
                <pubDate>Wed, 15 Dec 2021 13:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9723442</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/physician-innovator-advisor-ramin-rafie-md-028-1</link>
                                <description>
                                            <![CDATA[<p>Ramin Rafie, MD is an Internist trained in Geriatric, Hospice &amp; Palliative Medicine.</p><p>Dr. Rafie was born in Iran and grew up in Los Angeles, CA where he attended UCLA for his undergraduate degree, graduating with honors with a B.S. in Neuroscience.</p><p>Dr. Ramin attended the University of California, Irvine - School of Medicine and now practices in the Detroit, MI area. He is an active startup advisor and member of the AngelMD Sr. Clinical Advisory Team.<br /><br /></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Ramin Rafie, MD is an Internist trained in Geriatric, Hospice & Palliative Medicine.Dr. Rafie was born in Iran and grew up in Los Angeles, CA where he attended UCLA for his undergraduate degree, graduating with honors with a B.S. in Neuroscience.Dr. Ramin attended the University of California, Irvine - School of Medicine and now practices in the Detroit, MI area. He is an active startup advisor and member of the AngelMD Sr. Clinical Advisory Team.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Physician, Innovator & Advisor - Ramin Rafie, MD (028)]]>
                </itunes:title>
                                    <itunes:episode>28</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Ramin Rafie, MD is an Internist trained in Geriatric, Hospice &amp; Palliative Medicine.</p><p>Dr. Rafie was born in Iran and grew up in Los Angeles, CA where he attended UCLA for his undergraduate degree, graduating with honors with a B.S. in Neuroscience.</p><p>Dr. Ramin attended the University of California, Irvine - School of Medicine and now practices in the Detroit, MI area. He is an active startup advisor and member of the AngelMD Sr. Clinical Advisory Team.<br /><br /></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702597/c1e-w5k81irzz28f05j1d-qxnnp735f6ok-rnvvrx.mp3" length="22468048"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Ramin Rafie, MD is an Internist trained in Geriatric, Hospice & Palliative Medicine.Dr. Rafie was born in Iran and grew up in Los Angeles, CA where he attended UCLA for his undergraduate degree, graduating with honors with a B.S. in Neuroscience.Dr. Ramin attended the University of California, Irvine - School of Medicine and now practices in the Detroit, MI area. He is an active startup advisor and member of the AngelMD Sr. Clinical Advisory Team.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702597/c1a-3q87p-wnvv4r21f9jp-ledbie.jpeg"></itunes:image>
                                                                            <itunes:duration>00:31:11</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Matan Magril - Innovator, Investor and Guide (027)]]>
                </title>
                <pubDate>Fri, 26 Nov 2021 21:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9618452</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/matan-magril-innovator-investor-and-guide-027-1</link>
                                <description>
                                            <![CDATA[<p>One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he launched the full-scale event production and branding agency, Imperial Entertainment, which he successfully exited at 25 to join the founding team of Advocacy Asia, China’s first word-of-mouth platform.<br /><br />Matan is the Founder of FoodieTrip, the NYC-based marketing spearheads peer-to-peer marketplace that connects travelers to local food guides for authentic gastronomic experiences around the world. JetPack is the culmination of Matan’s decade-worth of experience founding and growing companies, as well as his passion for overhauling traditional capital raising.<br /><br />Through JetPack, Matan is able to provide uniquely exceptional startups with the guidance and support he sought when building his own ventures.<br /><br />Matan holds a B.A. in Finance from the University of Florida and Universita Bocconi in Milan.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he launched the full-scale event production and branding agency, Imperial Entertainment, which he successfully exited at 25 to join the founding team of Advocacy Asia, China’s first word-of-mouth platform.Matan is the Founder of FoodieTrip, the NYC-based marketing spearheads peer-to-peer marketplace that connects travelers to local food guides for authentic gastronomic experiences around the world. JetPack is the culmination of Matan’s decade-worth of experience founding and growing companies, as well as his passion for overhauling traditional capital raising.Through JetPack, Matan is able to provide uniquely exceptional startups with the guidance and support he sought when building his own ventures.Matan holds a B.A. in Finance from the University of Florida and Universita Bocconi in Milan.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Matan Magril - Innovator, Investor and Guide (027)]]>
                </itunes:title>
                                    <itunes:episode>27</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he launched the full-scale event production and branding agency, Imperial Entertainment, which he successfully exited at 25 to join the founding team of Advocacy Asia, China’s first word-of-mouth platform.<br /><br />Matan is the Founder of FoodieTrip, the NYC-based marketing spearheads peer-to-peer marketplace that connects travelers to local food guides for authentic gastronomic experiences around the world. JetPack is the culmination of Matan’s decade-worth of experience founding and growing companies, as well as his passion for overhauling traditional capital raising.<br /><br />Through JetPack, Matan is able to provide uniquely exceptional startups with the guidance and support he sought when building his own ventures.<br /><br />Matan holds a B.A. in Finance from the University of Florida and Universita Bocconi in Milan.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702598/c1e-z6jkvhm55rvio08gm-jkwwx78rim3m-4cnbvh.mp3" length="19757955"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he launched the full-scale event production and branding agency, Imperial Entertainment, which he successfully exited at 25 to join the founding team of Advocacy Asia, China’s first word-of-mouth platform.Matan is the Founder of FoodieTrip, the NYC-based marketing spearheads peer-to-peer marketplace that connects travelers to local food guides for authentic gastronomic experiences around the world. JetPack is the culmination of Matan’s decade-worth of experience founding and growing companies, as well as his passion for overhauling traditional capital raising.Through JetPack, Matan is able to provide uniquely exceptional startups with the guidance and support he sought when building his own ventures.Matan holds a B.A. in Finance from the University of Florida and Universita Bocconi in Milan.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702598/c1a-3q87p-jkwwx78ri6m7-2ntohv.jpg"></itunes:image>
                                                                            <itunes:duration>00:27:25</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Clinician Innovator: Asheesh Gupta, MD (026)]]>
                </title>
                <pubDate>Wed, 24 Nov 2021 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9607146</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/clinician-innovator-asheesh-gupta-md-026-1</link>
                                <description>
                                            <![CDATA[<p>Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD and as a member of the AngelMD Clinical Advisory Board. He specializes in hip arthroscopy and sports medicine at the Nova Orthopedic &amp; Spine Care division of The Centers in Woodbridge, Virginia. Dr. Gupta has gained hands-on experience in the sports medicine field through his fellowship with New York University Hospital for Joint Disease and his time with the New York Rangers, Chicago Sky and UIC Flames athletic program. In addition to his interest in sports medicine, Dr. Gupta specializes in hip arthroscopy and robotic assisted minimally-invasive total hip arthroplasty. In his spare time, Dr. Gupta enjoys staying active through soccer, tennis, running, biking and hiking.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD and as a member of the AngelMD Clinical Advisory Board. He specializes in hip arthroscopy and sports medicine at the Nova Orthopedic & Spine Care division of The Centers in Woodbridge, Virginia. Dr. Gupta has gained hands-on experience in the sports medicine field through his fellowship with New York University Hospital for Joint Disease and his time with the New York Rangers, Chicago Sky and UIC Flames athletic program. In addition to his interest in sports medicine, Dr. Gupta specializes in hip arthroscopy and robotic assisted minimally-invasive total hip arthroplasty. In his spare time, Dr. Gupta enjoys staying active through soccer, tennis, running, biking and hiking.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Clinician Innovator: Asheesh Gupta, MD (026)]]>
                </itunes:title>
                                    <itunes:episode>26</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD and as a member of the AngelMD Clinical Advisory Board. He specializes in hip arthroscopy and sports medicine at the Nova Orthopedic &amp; Spine Care division of The Centers in Woodbridge, Virginia. Dr. Gupta has gained hands-on experience in the sports medicine field through his fellowship with New York University Hospital for Joint Disease and his time with the New York Rangers, Chicago Sky and UIC Flames athletic program. In addition to his interest in sports medicine, Dr. Gupta specializes in hip arthroscopy and robotic assisted minimally-invasive total hip arthroplasty. In his spare time, Dr. Gupta enjoys staying active through soccer, tennis, running, biking and hiking.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702599/c1e-7w79ds422j6id3g34-60pp8rmvs1n2-g7p1os.mp3" length="11966758"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD and as a member of the AngelMD Clinical Advisory Board. He specializes in hip arthroscopy and sports medicine at the Nova Orthopedic & Spine Care division of The Centers in Woodbridge, Virginia. Dr. Gupta has gained hands-on experience in the sports medicine field through his fellowship with New York University Hospital for Joint Disease and his time with the New York Rangers, Chicago Sky and UIC Flames athletic program. In addition to his interest in sports medicine, Dr. Gupta specializes in hip arthroscopy and robotic assisted minimally-invasive total hip arthroplasty. In his spare time, Dr. Gupta enjoys staying active through soccer, tennis, running, biking and hiking.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702599/c1a-3q87p-mq33975zf38-g6uaeo.jpeg"></itunes:image>
                                                                            <itunes:duration>00:16:36</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Will Walker of Hall Venture Partners (025)]]>
                </title>
                <pubDate>Tue, 09 Nov 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9516839</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/will-walker-of-hall-venture-partners-025-1</link>
                                <description>
                                            <![CDATA[<p>Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that operates a massive incubation campus in Provo, UT called Hall Labs.<br /><br />Web site: www.hallvp.com<br /><br />Opportunity Zone talk: <a href="https://youtu.be/S8kqhrzn48Q">https://youtu.be/S8kqhrzn48Q</a></p><p>30 second video overview: <a href="https://vimeo.com/596778849/07635d0bfd">https://vimeo.com/596778849/07635d0bfd</a></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that operates a massive incubation campus in Provo, UT called Hall Labs.Web site: www.hallvp.comOpportunity Zone talk: https://youtu.be/S8kqhrzn48Q30 second video overview: https://vimeo.com/596778849/07635d0bfd]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Will Walker of Hall Venture Partners (025)]]>
                </itunes:title>
                                    <itunes:episode>25</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that operates a massive incubation campus in Provo, UT called Hall Labs.<br /><br />Web site: www.hallvp.com<br /><br />Opportunity Zone talk: <a href="https://youtu.be/S8kqhrzn48Q">https://youtu.be/S8kqhrzn48Q</a></p><p>30 second video overview: <a href="https://vimeo.com/596778849/07635d0bfd">https://vimeo.com/596778849/07635d0bfd</a></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702600/c1e-n5mzxi511r6a9289p-o8rr02x1sj3x-rda9ww.mp3" length="18812725"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that operates a massive incubation campus in Provo, UT called Hall Labs.Web site: www.hallvp.comOpportunity Zone talk: https://youtu.be/S8kqhrzn48Q30 second video overview: https://vimeo.com/596778849/07635d0bfd]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702600/c1a-3q87p-jkwwx78ri138-djulpr.jpeg"></itunes:image>
                                                                            <itunes:duration>00:26:07</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Embrace Prevention Care (024)]]>
                </title>
                <pubDate>Wed, 13 Oct 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9355180</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-embrace-prevention-care-024-1</link>
                                <description>
                                            <![CDATA[<p>Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that reduce preventable hospital stays. They partner with physicians to extend their reach into the home to help patients follow their prevention plans and drug regimens to achieve the goals that matter most to the patient while reducing the cost of care. Embrace is  the first to combine the tele-health care of local nurse practitioners with a geriatric pharmacy in their Prevention Care Platform to provide expert personalized geriatric preventive care to allow older adults to stay healthy, independent and age in place.<br /><br />AngelMD Profile: <a href="https://www.angelmd.co/en/startups/embrace-prevention-care">https://www.angelmd.co/en/startups/embrace-prevention-care</a></p><p><br /></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that reduce preventable hospital stays. They partner with physicians to extend their reach into the home to help patients follow their prevention plans and drug regimens to achieve the goals that matter most to the patient while reducing the cost of care. Embrace is  the first to combine the tele-health care of local nurse practitioners with a geriatric pharmacy in their Prevention Care Platform to provide expert personalized geriatric preventive care to allow older adults to stay healthy, independent and age in place.AngelMD Profile: https://www.angelmd.co/en/startups/embrace-prevention-care]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Embrace Prevention Care (024)]]>
                </itunes:title>
                                    <itunes:episode>24</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that reduce preventable hospital stays. They partner with physicians to extend their reach into the home to help patients follow their prevention plans and drug regimens to achieve the goals that matter most to the patient while reducing the cost of care. Embrace is  the first to combine the tele-health care of local nurse practitioners with a geriatric pharmacy in their Prevention Care Platform to provide expert personalized geriatric preventive care to allow older adults to stay healthy, independent and age in place.<br /><br />AngelMD Profile: <a href="https://www.angelmd.co/en/startups/embrace-prevention-care">https://www.angelmd.co/en/startups/embrace-prevention-care</a></p><p><br /></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702601/c1e-9pdqoinqq8vsdwj0p-jkwwx78rir64-w8cxgi.mp3" length="24069411"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that reduce preventable hospital stays. They partner with physicians to extend their reach into the home to help patients follow their prevention plans and drug regimens to achieve the goals that matter most to the patient while reducing the cost of care. Embrace is  the first to combine the tele-health care of local nurse practitioners with a geriatric pharmacy in their Prevention Care Platform to provide expert personalized geriatric preventive care to allow older adults to stay healthy, independent and age in place.AngelMD Profile: https://www.angelmd.co/en/startups/embrace-prevention-care]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702601/c1a-3q87p-rommgj9vb19-ritk7u.jpeg"></itunes:image>
                                                                            <itunes:duration>00:33:25</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Clinician Innovator & Investor: Geoff Colby, MD, PhD (022)]]>
                </title>
                <pubDate>Sun, 10 Oct 2021 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9343993</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/clinician-innovator-investor-geoff-colby-md-phd-022-1</link>
                                <description>
                                            <![CDATA[<p>Geoffrey Colby, MD, PhD is a neurosurgeon and expert specialist in the open microsurgical and minimally-invasive endovascular treatment of cerebrovascular disorders of the brain and spine. He is the Director of Cerebrovascular Neurosurgery and an Associate Professor of Neurosurgery and Radiology at UCLA. Dr. Colby is also the Director of the Neurosurgery Residency training Program at UCLA and Chair of the AngelMD Clinical Advisory Board Department of Neurosurgery.<br /><br />Dr. Colby is a world-class expert using flow diversion for treatment and cure of brain aneurysms. He is the only neurosurgeon on the West Coast certified to train and proctor physicians on the use of all FDA-approved flow diverting stents and intravascular devices for treatment of brain aneurysms. He is sought after to assist other specialists and provide guidance on complex aneurysm procedures across the country and internationally. He also performs embolization for subdural hematoma (SDH) and tumors of the brain and spine.<br /><br />Dr. Colby’s research explores technical advances to improve patient outcomes and the development of novel devices to treat cerebrovascular disorders. He has co-authored more than 100 peer-reviewed scientific articles and book chapters, and he has served as the principal investigator for many clinical studies testing new endovascular devices to treat cerebral aneurysms and stroke. He has lectured around the world on 4 continents, and he is a reviewer for the main scientific journals in the field of cerebrovascular disorders.<br /><br />Dr. Colby joined UCLA in 2017 from The Johns Hopkins University School of Medicine in Baltimore, where he was an Assistant Professor of Neurosurgery, Neurology and Radiology. During his tenure there, he performed thousands of neurosurgical procedures and was an avid researcher. His passion for teaching earned him the Department of Neurosurgery Chairman’s Award of Excellence, and the Neurosurgery house staff at Johns Hopkins presented him with the Richard J. Otenasek, Jr. Faculty Teaching Award. While at UCLA, he has been awarded similar honors for excellence in teaching and education, receiving the Ulrich Batzdorf, MD Gold Teaching Award.<br /><br />Dr. Colby received his MD and PhD degrees from Columbia University in New York City. He completed his internship and neurosurgery residency at The Johns Hopkins Hospital, as well as a two-year fellowship in endovascular neurosurgery and interventional neuroradiology. He joined the Johns Hopkins faculty in 2013.<br /><br />He is an avid outdoor enthusiast and has participated in triathlons, marathons, and mountaineering expeditions. He also enjoys casual jogs, bike riding, and hiking.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Geoffrey Colby, MD, PhD is a neurosurgeon and expert specialist in the open microsurgical and minimally-invasive endovascular treatment of cerebrovascular disorders of the brain and spine. He is the Director of Cerebrovascular Neurosurgery and an Associate Professor of Neurosurgery and Radiology at UCLA. Dr. Colby is also the Director of the Neurosurgery Residency training Program at UCLA and Chair of the AngelMD Clinical Advisory Board Department of Neurosurgery.Dr. Colby is a world-class expert using flow diversion for treatment and cure of brain aneurysms. He is the only neurosurgeon on the West Coast certified to train and proctor physicians on the use of all FDA-approved flow diverting stents and intravascular devices for treatment of brain aneurysms. He is sought after to assist other specialists and provide guidance on complex aneurysm procedures across the country and internationally. He also performs embolization for subdural hematoma (SDH) and tumors of the brain and spine.Dr. Colby’s research explores technical advances to improve patient outcomes and the development of novel devices to treat cerebrovascular disorders. He has co-authored more than 100 peer-reviewed scientific articles and book chapters, and he has served as the principal investigator for many clinical studies testing new endovascular devices to treat cerebral aneurysms and stroke. He has lectured around the world on 4 continents, and he is a reviewer for the main scientific journals in the field of cerebrovascular disorders.Dr. Colby joined UCLA in 2017 from The Johns Hopkins University School of Medicine in Baltimore, where he was an Assistant Professor of Neurosurgery, Neurology and Radiology. During his tenure there, he performed thousands of neurosurgical procedures and was an avid researcher. His passion for teaching earned him the Department of Neurosurgery Chairman’s Award of Excellence, and the Neurosurgery house staff at Johns Hopkins presented him with the Richard J. Otenasek, Jr. Faculty Teaching Award. While at UCLA, he has been awarded similar honors for excellence in teaching and education, receiving the Ulrich Batzdorf, MD Gold Teaching Award.Dr. Colby received his MD and PhD degrees from Columbia University in New York City. He completed his internship and neurosurgery residency at The Johns Hopkins Hospital, as well as a two-year fellowship in endovascular neurosurgery and interventional neuroradiology. He joined the Johns Hopkins faculty in 2013.He is an avid outdoor enthusiast and has participated in triathlons, marathons, and mountaineering expeditions. He also enjoys casual jogs, bike riding, and hiking.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Clinician Innovator & Investor: Geoff Colby, MD, PhD (022)]]>
                </itunes:title>
                                    <itunes:episode>22</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Geoffrey Colby, MD, PhD is a neurosurgeon and expert specialist in the open microsurgical and minimally-invasive endovascular treatment of cerebrovascular disorders of the brain and spine. He is the Director of Cerebrovascular Neurosurgery and an Associate Professor of Neurosurgery and Radiology at UCLA. Dr. Colby is also the Director of the Neurosurgery Residency training Program at UCLA and Chair of the AngelMD Clinical Advisory Board Department of Neurosurgery.<br /><br />Dr. Colby is a world-class expert using flow diversion for treatment and cure of brain aneurysms. He is the only neurosurgeon on the West Coast certified to train and proctor physicians on the use of all FDA-approved flow diverting stents and intravascular devices for treatment of brain aneurysms. He is sought after to assist other specialists and provide guidance on complex aneurysm procedures across the country and internationally. He also performs embolization for subdural hematoma (SDH) and tumors of the brain and spine.<br /><br />Dr. Colby’s research explores technical advances to improve patient outcomes and the development of novel devices to treat cerebrovascular disorders. He has co-authored more than 100 peer-reviewed scientific articles and book chapters, and he has served as the principal investigator for many clinical studies testing new endovascular devices to treat cerebral aneurysms and stroke. He has lectured around the world on 4 continents, and he is a reviewer for the main scientific journals in the field of cerebrovascular disorders.<br /><br />Dr. Colby joined UCLA in 2017 from The Johns Hopkins University School of Medicine in Baltimore, where he was an Assistant Professor of Neurosurgery, Neurology and Radiology. During his tenure there, he performed thousands of neurosurgical procedures and was an avid researcher. His passion for teaching earned him the Department of Neurosurgery Chairman’s Award of Excellence, and the Neurosurgery house staff at Johns Hopkins presented him with the Richard J. Otenasek, Jr. Faculty Teaching Award. While at UCLA, he has been awarded similar honors for excellence in teaching and education, receiving the Ulrich Batzdorf, MD Gold Teaching Award.<br /><br />Dr. Colby received his MD and PhD degrees from Columbia University in New York City. He completed his internship and neurosurgery residency at The Johns Hopkins Hospital, as well as a two-year fellowship in endovascular neurosurgery and interventional neuroradiology. He joined the Johns Hopkins faculty in 2013.<br /><br />He is an avid outdoor enthusiast and has participated in triathlons, marathons, and mountaineering expeditions. He also enjoys casual jogs, bike riding, and hiking.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702604/c1e-64532c2wwx4snj7zx-1xgg2v31hk5x-dh5kgm.mp3" length="13317133"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Geoffrey Colby, MD, PhD is a neurosurgeon and expert specialist in the open microsurgical and minimally-invasive endovascular treatment of cerebrovascular disorders of the brain and spine. He is the Director of Cerebrovascular Neurosurgery and an Associate Professor of Neurosurgery and Radiology at UCLA. Dr. Colby is also the Director of the Neurosurgery Residency training Program at UCLA and Chair of the AngelMD Clinical Advisory Board Department of Neurosurgery.Dr. Colby is a world-class expert using flow diversion for treatment and cure of brain aneurysms. He is the only neurosurgeon on the West Coast certified to train and proctor physicians on the use of all FDA-approved flow diverting stents and intravascular devices for treatment of brain aneurysms. He is sought after to assist other specialists and provide guidance on complex aneurysm procedures across the country and internationally. He also performs embolization for subdural hematoma (SDH) and tumors of the brain and spine.Dr. Colby’s research explores technical advances to improve patient outcomes and the development of novel devices to treat cerebrovascular disorders. He has co-authored more than 100 peer-reviewed scientific articles and book chapters, and he has served as the principal investigator for many clinical studies testing new endovascular devices to treat cerebral aneurysms and stroke. He has lectured around the world on 4 continents, and he is a reviewer for the main scientific journals in the field of cerebrovascular disorders.Dr. Colby joined UCLA in 2017 from The Johns Hopkins University School of Medicine in Baltimore, where he was an Assistant Professor of Neurosurgery, Neurology and Radiology. During his tenure there, he performed thousands of neurosurgical procedures and was an avid researcher. His passion for teaching earned him the Department of Neurosurgery Chairman’s Award of Excellence, and the Neurosurgery house staff at Johns Hopkins presented him with the Richard J. Otenasek, Jr. Faculty Teaching Award. While at UCLA, he has been awarded similar honors for excellence in teaching and education, receiving the Ulrich Batzdorf, MD Gold Teaching Award.Dr. Colby received his MD and PhD degrees from Columbia University in New York City. He completed his internship and neurosurgery residency at The Johns Hopkins Hospital, as well as a two-year fellowship in endovascular neurosurgery and interventional neuroradiology. He joined the Johns Hopkins faculty in 2013.He is an avid outdoor enthusiast and has participated in triathlons, marathons, and mountaineering expeditions. He also enjoys casual jogs, bike riding, and hiking.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702604/c1a-3q87p-gdqqj7gxhj61-kesynq.jpeg"></itunes:image>
                                                                            <itunes:duration>00:18:28</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Introducing Yuri Sernande - technologist, Innovator & Innovation4Alpha Executive Producer]]>
                </title>
                <pubDate>Sun, 10 Oct 2021 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9344039</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/introducing-yuri-sernande-technologist-innovator-innovation4alpha-executive-producer-1</link>
                                <description>
                                            <![CDATA[<p>Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a wide range of business and technical capacities across varied industries and nonprofits. He has a desire for developing and leading teams, strategic initiatives, streamlining key business processes, as well as creating innovative products, services, business models and platforms. <br /><br />Yuri has 20+ years of Management and Technology leadership experience. Working with leading-edge Hardware, Software as a Service and IoT technology companies. He especially enjoys working with organizations looking to employ the next generation of Digital Transformation Strategies. <br /><br />Previous to his career in technology, Yuri served as a Firefighter/EMT for 7 years and in the United States Army for 9 years.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a wide range of business and technical capacities across varied industries and nonprofits. He has a desire for developing and leading teams, strategic initiatives, streamlining key business processes, as well as creating innovative products, services, business models and platforms. Yuri has 20+ years of Management and Technology leadership experience. Working with leading-edge Hardware, Software as a Service and IoT technology companies. He especially enjoys working with organizations looking to employ the next generation of Digital Transformation Strategies. Previous to his career in technology, Yuri served as a Firefighter/EMT for 7 years and in the United States Army for 9 years.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Introducing Yuri Sernande - technologist, Innovator & Innovation4Alpha Executive Producer]]>
                </itunes:title>
                                    <itunes:episode>23</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a wide range of business and technical capacities across varied industries and nonprofits. He has a desire for developing and leading teams, strategic initiatives, streamlining key business processes, as well as creating innovative products, services, business models and platforms. <br /><br />Yuri has 20+ years of Management and Technology leadership experience. Working with leading-edge Hardware, Software as a Service and IoT technology companies. He especially enjoys working with organizations looking to employ the next generation of Digital Transformation Strategies. <br /><br />Previous to his career in technology, Yuri served as a Firefighter/EMT for 7 years and in the United States Army for 9 years.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702602/c1e-k1r97cjxx96i9z2jr-zo771m8jivww-kizqfg.mp3" length="11131870"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a wide range of business and technical capacities across varied industries and nonprofits. He has a desire for developing and leading teams, strategic initiatives, streamlining key business processes, as well as creating innovative products, services, business models and platforms. Yuri has 20+ years of Management and Technology leadership experience. Working with leading-edge Hardware, Software as a Service and IoT technology companies. He especially enjoys working with organizations looking to employ the next generation of Digital Transformation Strategies. Previous to his career in technology, Yuri served as a Firefighter/EMT for 7 years and in the United States Army for 9 years.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:15:26</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Matt Patsky, CEO of Trillium Asset Management (021)]]>
                </title>
                <pubDate>Sun, 26 Sep 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9260583</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/matt-patsky-ceo-of-trillium-asset-management-021-1</link>
                                <description>
                                            <![CDATA[<p>Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy. Matt has over three decades of experience in investment research and investment management. He began his career at Lehman Brothers in 1984 as a technology analyst. In 1989, while covering emerging growth companies for Lehman, he began to incorporate environmental, social, and governance factors into his research, becoming the first sell side analyst in the United States to publish on the topic of socially responsible investing in 1994. As Director of Equity Research for Adams, Harkness &amp; Hill, he built the firm’s powerful research capabilities in socially and environmentally responsible areas such as renewable energy, resource optimization, and organic and natural products. Before Trillium, Matt worked at Winslow Management Company in Boston, where he served as director of research, chairman of the investment committee, and portfolio manager for the Green Growth and Green Solutions Strategies.<br /><br />Matt currently serves on the board of TONIIC and has previously served on the Boards of Environmental League of Massachusetts, Shared Interest, Pro Mujer, US SIF, and Root Capital. He is also a member of the Social Venture Circle (SVC) and is a member of the CFA Society Boston and is a Chartered Financial Analyst charterholder.<br /><br />Trillium Asset Management is at the forefront of thought leadership and continues to draw from decades of experience focused exclusively on responsible investing. Trillium’s founder, Joan Bavaria, was a true visionary and served as an early catalyst for change in the investment industry. The firm’s innovative approach led to the creation of numerous organizations, the development of the ESG investment field, and the first generation of investors focused on improved environmental, social, and governance outcomes.<br /><br />Today, the firm is an impact-driven, ESG-focused firm dedicated to aligning values with investment objectives. Trillium’s commitment to active ownership and shareholder advocacy has contributed to concrete and positive change.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy. Matt has over three decades of experience in investment research and investment management. He began his career at Lehman Brothers in 1984 as a technology analyst. In 1989, while covering emerging growth companies for Lehman, he began to incorporate environmental, social, and governance factors into his research, becoming the first sell side analyst in the United States to publish on the topic of socially responsible investing in 1994. As Director of Equity Research for Adams, Harkness & Hill, he built the firm’s powerful research capabilities in socially and environmentally responsible areas such as renewable energy, resource optimization, and organic and natural products. Before Trillium, Matt worked at Winslow Management Company in Boston, where he served as director of research, chairman of the investment committee, and portfolio manager for the Green Growth and Green Solutions Strategies.Matt currently serves on the board of TONIIC and has previously served on the Boards of Environmental League of Massachusetts, Shared Interest, Pro Mujer, US SIF, and Root Capital. He is also a member of the Social Venture Circle (SVC) and is a member of the CFA Society Boston and is a Chartered Financial Analyst charterholder.Trillium Asset Management is at the forefront of thought leadership and continues to draw from decades of experience focused exclusively on responsible investing. Trillium’s founder, Joan Bavaria, was a true visionary and served as an early catalyst for change in the investment industry. The firm’s innovative approach led to the creation of numerous organizations, the development of the ESG investment field, and the first generation of investors focused on improved environmental, social, and governance outcomes.Today, the firm is an impact-driven, ESG-focused firm dedicated to aligning values with investment objectives. Trillium’s commitment to active ownership and shareholder advocacy has contributed to concrete and positive change.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Matt Patsky, CEO of Trillium Asset Management (021)]]>
                </itunes:title>
                                    <itunes:episode>21</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy. Matt has over three decades of experience in investment research and investment management. He began his career at Lehman Brothers in 1984 as a technology analyst. In 1989, while covering emerging growth companies for Lehman, he began to incorporate environmental, social, and governance factors into his research, becoming the first sell side analyst in the United States to publish on the topic of socially responsible investing in 1994. As Director of Equity Research for Adams, Harkness &amp; Hill, he built the firm’s powerful research capabilities in socially and environmentally responsible areas such as renewable energy, resource optimization, and organic and natural products. Before Trillium, Matt worked at Winslow Management Company in Boston, where he served as director of research, chairman of the investment committee, and portfolio manager for the Green Growth and Green Solutions Strategies.<br /><br />Matt currently serves on the board of TONIIC and has previously served on the Boards of Environmental League of Massachusetts, Shared Interest, Pro Mujer, US SIF, and Root Capital. He is also a member of the Social Venture Circle (SVC) and is a member of the CFA Society Boston and is a Chartered Financial Analyst charterholder.<br /><br />Trillium Asset Management is at the forefront of thought leadership and continues to draw from decades of experience focused exclusively on responsible investing. Trillium’s founder, Joan Bavaria, was a true visionary and served as an early catalyst for change in the investment industry. The firm’s innovative approach led to the creation of numerous organizations, the development of the ESG investment field, and the first generation of investors focused on improved environmental, social, and governance outcomes.<br /><br />Today, the firm is an impact-driven, ESG-focused firm dedicated to aligning values with investment objectives. Trillium’s commitment to active ownership and shareholder advocacy has contributed to concrete and positive change.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702603/c1e-d3q2gh6vvg5cpwzjx-8m778n17fk0-ylrtxp.mp3" length="24175286"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy. Matt has over three decades of experience in investment research and investment management. He began his career at Lehman Brothers in 1984 as a technology analyst. In 1989, while covering emerging growth companies for Lehman, he began to incorporate environmental, social, and governance factors into his research, becoming the first sell side analyst in the United States to publish on the topic of socially responsible investing in 1994. As Director of Equity Research for Adams, Harkness & Hill, he built the firm’s powerful research capabilities in socially and environmentally responsible areas such as renewable energy, resource optimization, and organic and natural products. Before Trillium, Matt worked at Winslow Management Company in Boston, where he served as director of research, chairman of the investment committee, and portfolio manager for the Green Growth and Green Solutions Strategies.Matt currently serves on the board of TONIIC and has previously served on the Boards of Environmental League of Massachusetts, Shared Interest, Pro Mujer, US SIF, and Root Capital. He is also a member of the Social Venture Circle (SVC) and is a member of the CFA Society Boston and is a Chartered Financial Analyst charterholder.Trillium Asset Management is at the forefront of thought leadership and continues to draw from decades of experience focused exclusively on responsible investing. Trillium’s founder, Joan Bavaria, was a true visionary and served as an early catalyst for change in the investment industry. The firm’s innovative approach led to the creation of numerous organizations, the development of the ESG investment field, and the first generation of investors focused on improved environmental, social, and governance outcomes.Today, the firm is an impact-driven, ESG-focused firm dedicated to aligning values with investment objectives. Trillium’s commitment to active ownership and shareholder advocacy has contributed to concrete and positive change.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702603/c1a-3q87p-dd77j80qh901-kspwoc.jpeg"></itunes:image>
                                                                            <itunes:duration>00:33:34</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Lactiga (020)]]>
                </title>
                <pubDate>Sun, 05 Sep 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9140761</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-lactiga-020-1</link>
                                <description>
                                            <![CDATA[<p>Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe &amp; Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.<br /><br />AngelMD Profile: https://www.angelmd.co/en/startups/lactiga</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.AngelMD Profile: https://www.angelmd.co/en/startups/lactiga]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Lactiga (020)]]>
                </itunes:title>
                                    <itunes:episode>20</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe &amp; Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.<br /><br />AngelMD Profile: https://www.angelmd.co/en/startups/lactiga</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702605/c1e-0qgpztjoo44ugo8w2-k5xxoqvxapq8-ggvz6i.mp3" length="35180304"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.AngelMD Profile: https://www.angelmd.co/en/startups/lactiga]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702605/c1a-3q87p-92kkgmzkso0x-fgb7qb.jpg"></itunes:image>
                                                                            <itunes:duration>00:48:50</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Julie Anderson of Cambia Grove (018)]]>
                </title>
                <pubDate>Mon, 30 Aug 2021 02:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9099321</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/julie-anderson-of-cambia-grove-018-1</link>
                                <description>
                                            <![CDATA[<p><a href="https://www.cambiagrove.com/julie-panek-anderson">Julie Anderson</a> is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.<br /><br />Cambia Grove is a health care innovation hub focused on bridging the gap between entrepreneurs and the traditional health care sectors. <br /><br />Formed by a large payor, the organization sits in an interesting spot to help startups navigate some of the complexities of healthcare, reimbursements and more.</p><p><br />Cambia Grove Goals:</p><ul><li>Build Community: Connect, nurture and expand a community of health care change-makers to support development of new health care solutions</li><li>Catalyze Solutions: Catalyze solutions to system level challenges in health care</li><li>Advance Innovation: Advance innovative efforts to create a more person focused and economically sustainable health care system</li></ul><p><a href="https://www.cambiagrove.com/">www.cambiagrove.com</a><br /><br /><a href="https://www.cambiagrove.com/programs-and-initiatives/trails-competition">https://www.cambiagrove.com/programs-and-initiatives/trails-competition</a><br /><br /><a href="https://www.cambiagrove.com/cambia-grove-membership">https://www.cambiagrove.com/cambia-grove-membership</a></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Julie Anderson is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.Cambia Grove is a health care innovation hub focused on bridging the gap between entrepreneurs and the traditional health care sectors. Formed by a large payor, the organization sits in an interesting spot to help startups navigate some of the complexities of healthcare, reimbursements and more.Cambia Grove Goals:Build Community: Connect, nurture and expand a community of health care change-makers to support development of new health care solutionsCatalyze Solutions: Catalyze solutions to system level challenges in health careAdvance Innovation: Advance innovative efforts to create a more person focused and economically sustainable health care systemwww.cambiagrove.comhttps://www.cambiagrove.com/programs-and-initiatives/trails-competitionhttps://www.cambiagrove.com/cambia-grove-membership]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Julie Anderson of Cambia Grove (018)]]>
                </itunes:title>
                                    <itunes:episode>18</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><a href="https://www.cambiagrove.com/julie-panek-anderson">Julie Anderson</a> is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.<br /><br />Cambia Grove is a health care innovation hub focused on bridging the gap between entrepreneurs and the traditional health care sectors. <br /><br />Formed by a large payor, the organization sits in an interesting spot to help startups navigate some of the complexities of healthcare, reimbursements and more.</p><p><br />Cambia Grove Goals:</p><ul><li>Build Community: Connect, nurture and expand a community of health care change-makers to support development of new health care solutions</li><li>Catalyze Solutions: Catalyze solutions to system level challenges in health care</li><li>Advance Innovation: Advance innovative efforts to create a more person focused and economically sustainable health care system</li></ul><p><a href="https://www.cambiagrove.com/">www.cambiagrove.com</a><br /><br /><a href="https://www.cambiagrove.com/programs-and-initiatives/trails-competition">https://www.cambiagrove.com/programs-and-initiatives/trails-competition</a><br /><br /><a href="https://www.cambiagrove.com/cambia-grove-membership">https://www.cambiagrove.com/cambia-grove-membership</a></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702607/c1e-w5k81irzz2nc06k67-zo771mgzu2p3-hd4lp1.mp3" length="30640652"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Julie Anderson is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.Cambia Grove is a health care innovation hub focused on bridging the gap between entrepreneurs and the traditional health care sectors. Formed by a large payor, the organization sits in an interesting spot to help startups navigate some of the complexities of healthcare, reimbursements and more.Cambia Grove Goals:Build Community: Connect, nurture and expand a community of health care change-makers to support development of new health care solutionsCatalyze Solutions: Catalyze solutions to system level challenges in health careAdvance Innovation: Advance innovative efforts to create a more person focused and economically sustainable health care systemwww.cambiagrove.comhttps://www.cambiagrove.com/programs-and-initiatives/trails-competitionhttps://www.cambiagrove.com/cambia-grove-membership]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702607/c1a-3q87p-8m778n17fdxg-4qp4ck.jpeg"></itunes:image>
                                                                            <itunes:duration>00:42:32</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Elims (017)]]>
                </title>
                <pubDate>Wed, 25 Aug 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9081338</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-elims-017-1</link>
                                <description>
                                            <![CDATA[<p>Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health for the planet. That's why Elims is not just  sustainable. Each of their products are crafted by dentists, biotech professionals and sustainability experts, and they actually work at keeping your teeth clean and sparkling white. They combine the best of science + nature by only using clinically backed and tested ingredients to effective natural ones to bring your oral care for everyone.<br /><br />https://www.angelmd.co/en/startups/elims</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health for the planet. That's why Elims is not just  sustainable. Each of their products are crafted by dentists, biotech professionals and sustainability experts, and they actually work at keeping your teeth clean and sparkling white. They combine the best of science + nature by only using clinically backed and tested ingredients to effective natural ones to bring your oral care for everyone.https://www.angelmd.co/en/startups/elims]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Elims (017)]]>
                </itunes:title>
                                    <itunes:episode>17</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health for the planet. That's why Elims is not just  sustainable. Each of their products are crafted by dentists, biotech professionals and sustainability experts, and they actually work at keeping your teeth clean and sparkling white. They combine the best of science + nature by only using clinically backed and tested ingredients to effective natural ones to bring your oral care for everyone.<br /><br />https://www.angelmd.co/en/startups/elims</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702606/c1e-g0xz8i3ww28f254x7-92kkgm85f6g-9flae6.mp3" length="22051495"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health for the planet. That's why Elims is not just  sustainable. Each of their products are crafted by dentists, biotech professionals and sustainability experts, and they actually work at keeping your teeth clean and sparkling white. They combine the best of science + nature by only using clinically backed and tested ingredients to effective natural ones to bring your oral care for everyone.https://www.angelmd.co/en/startups/elims]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702606/c1a-3q87p-8m778nz9ap94-mcbnzh.jpg"></itunes:image>
                                                                            <itunes:duration>00:30:35</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Featured Startup: iVizz (019)]]>
                </title>
                <pubDate>Wed, 25 Aug 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-9080776</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/featured-startup-ivizz-019-1</link>
                                <description>
                                            <![CDATA[<p>iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.<br /><br /><a href="https://www.angelmd.co/en/startups/ivizz">https://www.angelmd.co/en/startups/ivizz</a></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.https://www.angelmd.co/en/startups/ivizz]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Featured Startup: iVizz (019)]]>
                </itunes:title>
                                    <itunes:episode>19</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.<br /><br /><a href="https://www.angelmd.co/en/startups/ivizz">https://www.angelmd.co/en/startups/ivizz</a></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702608/c1e-k1r97cjxx2mh9zk2r-zo771mgzur4-vrva9e.mp3" length="18628904"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[iVizz, is a Bay Area technology company which enables hospitals to prevent in-patient infections outbreaks.https://www.angelmd.co/en/startups/ivizz]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702608/c1a-3q87p-v088v9mncq2p-os3sdt.jpg"></itunes:image>
                                                                            <itunes:duration>00:25:51</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Featured Family Office: Nottingham Spirk / Katherine Hill Ritchie (016)]]>
                </title>
                <pubDate>Wed, 04 Aug 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8963167</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/featured-family-office-nottingham-spirk-katherine-hill-ritchie-016-1</link>
                                <description>
                                            <![CDATA[<p>Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both investment sourcing and project sourcing for a Cleveland based family office rooted in industry design.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both investment sourcing and project sourcing for a Cleveland based family office rooted in industry design.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Featured Family Office: Nottingham Spirk / Katherine Hill Ritchie (016)]]>
                </itunes:title>
                                    <itunes:episode>16</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both investment sourcing and project sourcing for a Cleveland based family office rooted in industry design.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702609/c1e-jg935sq119mtnojq4-7n55801ksgmg-0yvtxh.mp3" length="25600070"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both investment sourcing and project sourcing for a Cleveland based family office rooted in industry design.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702609/c1a-3q87p-dd77j895tx6q-eppeun.jpg"></itunes:image>
                                                                            <itunes:duration>00:35:31</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Featured Startup: AvodahMed (015)]]>
                </title>
                <pubDate>Wed, 28 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8935541</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/featured-startup-avodahmed-015-1</link>
                                <description>
                                            <![CDATA[<p>AvodahMed is an advanced technology company improving quality care for patients and healthcare providers. They provide a unique solution that embeds AI throughout live video conferencing with computer vision, real-time language translation, and patient vitals informing both patient and doctor in new and novel ways. They facilitate an experience aimed to exceed a live visit.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[AvodahMed is an advanced technology company improving quality care for patients and healthcare providers. They provide a unique solution that embeds AI throughout live video conferencing with computer vision, real-time language translation, and patient vitals informing both patient and doctor in new and novel ways. They facilitate an experience aimed to exceed a live visit.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Featured Startup: AvodahMed (015)]]>
                </itunes:title>
                                    <itunes:episode>15</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>AvodahMed is an advanced technology company improving quality care for patients and healthcare providers. They provide a unique solution that embeds AI throughout live video conferencing with computer vision, real-time language translation, and patient vitals informing both patient and doctor in new and novel ways. They facilitate an experience aimed to exceed a live visit.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702610/c1e-q2zo9u2pp1zb0ko6w-o8rr0253av7p-npyvsc.mp3" length="20351593"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[AvodahMed is an advanced technology company improving quality care for patients and healthcare providers. They provide a unique solution that embeds AI throughout live video conferencing with computer vision, real-time language translation, and patient vitals informing both patient and doctor in new and novel ways. They facilitate an experience aimed to exceed a live visit.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702610/c1a-3q87p-92kkgmz4u55v-bdhpwc.jpg"></itunes:image>
                                                                            <itunes:duration>00:28:15</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Featured Family Office / Incubator: Hall Venture Partners (014)]]>
                </title>
                <pubDate>Wed, 28 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8935525</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/featured-family-office-incubator-hall-venture-partners-014-1</link>
                                <description>
                                            <![CDATA[<p>Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing demand by investors for curated opportunities in early growth technology companies and an opportunity to co-invest alongside the Hall Family in ventures throughout their modern Edison Labs ecosystem.<br /><br />The Hall Venture Partners team are a seasoned and successful management group that supports patent-protected companies and helps them grow. They are industry agnostic and have expertise in consumer goods, automotive technology, building automation and controls, high temperature electronics and healthcare. They are focused on the commercialization and growth of technologies that were developed to tackle some of the world’s most challenging problems.<br /><br /></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing demand by investors for curated opportunities in early growth technology companies and an opportunity to co-invest alongside the Hall Family in ventures throughout their modern Edison Labs ecosystem.The Hall Venture Partners team are a seasoned and successful management group that supports patent-protected companies and helps them grow. They are industry agnostic and have expertise in consumer goods, automotive technology, building automation and controls, high temperature electronics and healthcare. They are focused on the commercialization and growth of technologies that were developed to tackle some of the world’s most challenging problems.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Featured Family Office / Incubator: Hall Venture Partners (014)]]>
                </itunes:title>
                                    <itunes:episode>14</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing demand by investors for curated opportunities in early growth technology companies and an opportunity to co-invest alongside the Hall Family in ventures throughout their modern Edison Labs ecosystem.<br /><br />The Hall Venture Partners team are a seasoned and successful management group that supports patent-protected companies and helps them grow. They are industry agnostic and have expertise in consumer goods, automotive technology, building automation and controls, high temperature electronics and healthcare. They are focused on the commercialization and growth of technologies that were developed to tackle some of the world’s most challenging problems.<br /><br /></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702612/c1e-v574gi9rr38fwd86z-7n558012urpd-fgdiba.mp3" length="25349480"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing demand by investors for curated opportunities in early growth technology companies and an opportunity to co-invest alongside the Hall Family in ventures throughout their modern Edison Labs ecosystem.The Hall Venture Partners team are a seasoned and successful management group that supports patent-protected companies and helps them grow. They are industry agnostic and have expertise in consumer goods, automotive technology, building automation and controls, high temperature electronics and healthcare. They are focused on the commercialization and growth of technologies that were developed to tackle some of the world’s most challenging problems.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702612/c1a-3q87p-rommgjxzcm7w-4dr6ld.jpg"></itunes:image>
                                                                            <itunes:duration>00:35:12</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Innovator: Unity Stoakes, Startup Health (013)]]>
                </title>
                <pubDate>Mon, 26 Jul 2021 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8923930</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/innovator-unity-stoakes-startup-health-013-1</link>
                                <description>
                                            <![CDATA[<p>Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which are based on key areas of healthcare innovation need around the world. The group has a new Impact Fund which enables investors to participate in their prolific investment activity on a quarter by quarter basis.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which are based on key areas of healthcare innovation need around the world. The group has a new Impact Fund which enables investors to participate in their prolific investment activity on a quarter by quarter basis.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Innovator: Unity Stoakes, Startup Health (013)]]>
                </itunes:title>
                                    <itunes:episode>13</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which are based on key areas of healthcare innovation need around the world. The group has a new Impact Fund which enables investors to participate in their prolific investment activity on a quarter by quarter basis.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702611/c1e-8pkqxi9qqjqu19r8g-xmppk0n8amq3-p8qshj.mp3" length="29817863"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which are based on key areas of healthcare innovation need around the world. The group has a new Impact Fund which enables investors to participate in their prolific investment activity on a quarter by quarter basis.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702611/c1a-3q87p-33225o0khd41-4w5i2k.jpg"></itunes:image>
                                                                            <itunes:duration>00:41:24</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Clinician Innovator and Investor: Jeremy Krell, DMD (012)]]>
                </title>
                <pubDate>Wed, 21 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8891220</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/clinician-innovator-and-investor-jeremy-krell-dmd-012-1</link>
                                <description>
                                            <![CDATA[<p>Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC, and the Chief Marketing Officer of Verena Solutions, based in Chicago. He oversaw provider and clinical growth initiatives at quip, the oral health and subscription electric toothbrush company, and has since built out the Barchester Bay Group, a portfolio consisting of over 15 ventures.<br /><br />Jeremy practices general dentistry part-time, sits on the Boards of healthcare and dental startups, and is an angel investor. Jeremy has a 15+ year proven track record with startups through several successful multi-million dollar fundraises and acquisitions.<br /><br />Jeremy started his career with three web and graphic design startups and moved into a luxury good and commodity venture, DormAid, for college students. He later founded a venture incubator, CEO in A Box, and led strategic provider innovation and development at Oscar, a national health insurance company, following his MBA at Chicago Booth.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC, and the Chief Marketing Officer of Verena Solutions, based in Chicago. He oversaw provider and clinical growth initiatives at quip, the oral health and subscription electric toothbrush company, and has since built out the Barchester Bay Group, a portfolio consisting of over 15 ventures.Jeremy practices general dentistry part-time, sits on the Boards of healthcare and dental startups, and is an angel investor. Jeremy has a 15+ year proven track record with startups through several successful multi-million dollar fundraises and acquisitions.Jeremy started his career with three web and graphic design startups and moved into a luxury good and commodity venture, DormAid, for college students. He later founded a venture incubator, CEO in A Box, and led strategic provider innovation and development at Oscar, a national health insurance company, following his MBA at Chicago Booth.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Clinician Innovator and Investor: Jeremy Krell, DMD (012)]]>
                </itunes:title>
                                    <itunes:episode>12</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC, and the Chief Marketing Officer of Verena Solutions, based in Chicago. He oversaw provider and clinical growth initiatives at quip, the oral health and subscription electric toothbrush company, and has since built out the Barchester Bay Group, a portfolio consisting of over 15 ventures.<br /><br />Jeremy practices general dentistry part-time, sits on the Boards of healthcare and dental startups, and is an angel investor. Jeremy has a 15+ year proven track record with startups through several successful multi-million dollar fundraises and acquisitions.<br /><br />Jeremy started his career with three web and graphic design startups and moved into a luxury good and commodity venture, DormAid, for college students. He later founded a venture incubator, CEO in A Box, and led strategic provider innovation and development at Oscar, a national health insurance company, following his MBA at Chicago Booth.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702613/c1e-8pkqxi9qqj9c1pxm5-v088v9rdipk8-3ckbml.mp3" length="32087235"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC, and the Chief Marketing Officer of Verena Solutions, based in Chicago. He oversaw provider and clinical growth initiatives at quip, the oral health and subscription electric toothbrush company, and has since built out the Barchester Bay Group, a portfolio consisting of over 15 ventures.Jeremy practices general dentistry part-time, sits on the Boards of healthcare and dental startups, and is an angel investor. Jeremy has a 15+ year proven track record with startups through several successful multi-million dollar fundraises and acquisitions.Jeremy started his career with three web and graphic design startups and moved into a luxury good and commodity venture, DormAid, for college students. He later founded a venture incubator, CEO in A Box, and led strategic provider innovation and development at Oscar, a national health insurance company, following his MBA at Chicago Booth.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:44:33</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Eyetamins (011)]]>
                </title>
                <pubDate>Sun, 18 Jul 2021 17:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8879037</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-eyetamins-011-1</link>
                                <description>
                                            <![CDATA[<p>Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They launched the company with natural supplements for eye health, which is a $37B industry. They have a patent-pending formula for dry eye, which is an $8B untapped market.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They launched the company with natural supplements for eye health, which is a $37B industry. They have a patent-pending formula for dry eye, which is an $8B untapped market.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Eyetamins (011)]]>
                </itunes:title>
                                    <itunes:episode>11</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They launched the company with natural supplements for eye health, which is a $37B industry. They have a patent-pending formula for dry eye, which is an $8B untapped market.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702615/c1e-jg935sq1194an522w-8m778nzrim3r-8plls6.mp3" length="17139928"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They launched the company with natural supplements for eye health, which is a $37B industry. They have a patent-pending formula for dry eye, which is an $8B untapped market.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702615/c1a-3q87p-5rvvq9m1s63n-a4soav.jpg"></itunes:image>
                                                                            <itunes:duration>00:23:48</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: SurgiQuality (010)]]>
                </title>
                <pubDate>Sun, 11 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8816145</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-surgiquality-010-1</link>
                                <description>
                                            <![CDATA[<p>Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: SurgiQuality (010)]]>
                </itunes:title>
                                    <itunes:episode>7</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702614/c1e-r583rijmmgwu28n5p-nj99rk2ot60k-dbqaej.mp3" length="13398729"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702614/c1a-3q87p-dd77j894sjr-pjpliz.jpg"></itunes:image>
                                                                            <itunes:duration>00:18:36</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Happyr Health (009)]]>
                </title>
                <pubDate>Fri, 09 Jul 2021 17:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8837996</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-happyr-health-009-1</link>
                                <description>
                                            <![CDATA[<p>Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with chronic conditions and their families by implementing treatment plans, lifestyle changes and personalized psychological exercises through a novel "game-ified" mobile application.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with chronic conditions and their families by implementing treatment plans, lifestyle changes and personalized psychological exercises through a novel "game-ified" mobile application.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Happyr Health (009)]]>
                </itunes:title>
                                    <itunes:episode>9</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with chronic conditions and their families by implementing treatment plans, lifestyle changes and personalized psychological exercises through a novel "game-ified" mobile application.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702616/c1e-k1r97cjxx28c9gzvn-mq3397v4uknm-xiqjow.mp3" length="9229204"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with chronic conditions and their families by implementing treatment plans, lifestyle changes and personalized psychological exercises through a novel "game-ified" mobile application.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702616/c1a-3q87p-5rvvq9m1sd3r-nkpclg.jpg"></itunes:image>
                                                                            <itunes:duration>00:12:49</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Recalibrate Solutions (008)]]>
                </title>
                <pubDate>Fri, 09 Jul 2021 16:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8837697</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-recalibrate-solutions-008-1</link>
                                <description>
                                            <![CDATA[<p>Recalibrate Solutions (RS) is creating a stethoscope for stress health monitoring of kids. It’s a 5-minute, disposable cortisol test that helps identify kids suffering from toxic stress and get them connected to the help they need. The problem is toxic stress affects 17% of all US children and costs the healthcare system $748 billion each year, yet physicians have no objective way to identify who’s suffering. With the RS tools, the medical community can identify early signs of toxic stress in 5-minutes and connect kids to the help they need. What differentiates Recalibrate Solutions is the monitoring of stress biology. Current tools only assess a child’s RISK for adversity based on 10 experiences identified in the 1990s (ACEs). RS makes money with a razor/razor-blade model - a disposable, 5-minute test, evaluated using a small medical instrument.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Recalibrate Solutions (RS) is creating a stethoscope for stress health monitoring of kids. It’s a 5-minute, disposable cortisol test that helps identify kids suffering from toxic stress and get them connected to the help they need. The problem is toxic stress affects 17% of all US children and costs the healthcare system $748 billion each year, yet physicians have no objective way to identify who’s suffering. With the RS tools, the medical community can identify early signs of toxic stress in 5-minutes and connect kids to the help they need. What differentiates Recalibrate Solutions is the monitoring of stress biology. Current tools only assess a child’s RISK for adversity based on 10 experiences identified in the 1990s (ACEs). RS makes money with a razor/razor-blade model - a disposable, 5-minute test, evaluated using a small medical instrument.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Recalibrate Solutions (008)]]>
                </itunes:title>
                                    <itunes:episode>8</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Recalibrate Solutions (RS) is creating a stethoscope for stress health monitoring of kids. It’s a 5-minute, disposable cortisol test that helps identify kids suffering from toxic stress and get them connected to the help they need. The problem is toxic stress affects 17% of all US children and costs the healthcare system $748 billion each year, yet physicians have no objective way to identify who’s suffering. With the RS tools, the medical community can identify early signs of toxic stress in 5-minutes and connect kids to the help they need. What differentiates Recalibrate Solutions is the monitoring of stress biology. Current tools only assess a child’s RISK for adversity based on 10 experiences identified in the 1990s (ACEs). RS makes money with a razor/razor-blade model - a disposable, 5-minute test, evaluated using a small medical instrument.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702617/c1e-0qgpztjoo0qhgjd0m-8m778nzqt9d5-ykvnrw.mp3" length="9984633"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Recalibrate Solutions (RS) is creating a stethoscope for stress health monitoring of kids. It’s a 5-minute, disposable cortisol test that helps identify kids suffering from toxic stress and get them connected to the help they need. The problem is toxic stress affects 17% of all US children and costs the healthcare system $748 billion each year, yet physicians have no objective way to identify who’s suffering. With the RS tools, the medical community can identify early signs of toxic stress in 5-minutes and connect kids to the help they need. What differentiates Recalibrate Solutions is the monitoring of stress biology. Current tools only assess a child’s RISK for adversity based on 10 experiences identified in the 1990s (ACEs). RS makes money with a razor/razor-blade model - a disposable, 5-minute test, evaluated using a small medical instrument.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702617/c1a-3q87p-zo771mg2h8z0-f8q9kq.jpeg"></itunes:image>
                                                                            <itunes:duration>00:13:50</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Andrew Malloy on Family Office Impact Investing (007)]]>
                </title>
                <pubDate>Fri, 09 Jul 2021 15:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8837498</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/andrew-malloy-on-family-office-impact-investing-007-1</link>
                                <description>
                                            <![CDATA[<p>Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his family's successful history in the retail industry. He shares his insights about family office interest in being involved in impact investing.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his family's successful history in the retail industry. He shares his insights about family office interest in being involved in impact investing.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Andrew Malloy on Family Office Impact Investing (007)]]>
                </itunes:title>
                                    <itunes:episode>7</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his family's successful history in the retail industry. He shares his insights about family office interest in being involved in impact investing.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702619/c1e-d3q2gh6vvp1upjxv2-1xgg2v97cwdv-w5t2l0.mp3" length="13843405"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his family's successful history in the retail industry. He shares his insights about family office interest in being involved in impact investing.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702619/c1a-3q87p-dd77j892fm2m-zpdhde.jpeg"></itunes:image>
                                                                            <itunes:duration>00:19:12</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Healthcare Impact Investing Summit & ESG Investing (006)]]>
                </title>
                <pubDate>Wed, 07 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8816003</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/healthcare-impact-investing-summit-esg-investing-006-1</link>
                                <description>
                                            <![CDATA[<p>On July 13, 2021, AngelMD is hosting the Healthcare Impact Investing Summit with a coalition of partners all focused on improving innovation in healthcare. The event was born out of frustration with what is often billed as "Impact Investing" but instead is fee based social engineering at the expense of American retirees. Instead, impact investing in healthcare has potential for sizable returns while also working to solve real healthcare challenges that will affect all of us and our families at one time or another.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[On July 13, 2021, AngelMD is hosting the Healthcare Impact Investing Summit with a coalition of partners all focused on improving innovation in healthcare. The event was born out of frustration with what is often billed as "Impact Investing" but instead is fee based social engineering at the expense of American retirees. Instead, impact investing in healthcare has potential for sizable returns while also working to solve real healthcare challenges that will affect all of us and our families at one time or another.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Healthcare Impact Investing Summit & ESG Investing (006)]]>
                </itunes:title>
                                    <itunes:episode>6</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>On July 13, 2021, AngelMD is hosting the Healthcare Impact Investing Summit with a coalition of partners all focused on improving innovation in healthcare. The event was born out of frustration with what is often billed as "Impact Investing" but instead is fee based social engineering at the expense of American retirees. Instead, impact investing in healthcare has potential for sizable returns while also working to solve real healthcare challenges that will affect all of us and our families at one time or another.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702618/c1e-odgzobv00zmf871k0-8m778nzqtg7n-jmh0vm.mp3" length="4235216"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[On July 13, 2021, AngelMD is hosting the Healthcare Impact Investing Summit with a coalition of partners all focused on improving innovation in healthcare. The event was born out of frustration with what is often billed as "Impact Investing" but instead is fee based social engineering at the expense of American retirees. Instead, impact investing in healthcare has potential for sizable returns while also working to solve real healthcare challenges that will affect all of us and our families at one time or another.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702618/c1a-3q87p-jkwwx71da6vp-7hnsjd.jpeg"></itunes:image>
                                                                            <itunes:duration>00:05:52</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: RiskLD (005)]]>
                </title>
                <pubDate>Sun, 04 Jul 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8806749</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-riskld-005-1</link>
                                <description>
                                            <![CDATA[<p>RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: RiskLD (005)]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702621/c1e-d3q2gh6vvpncp53nm-p800n27wunwz-rurirz.mp3" length="25614036"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:35:33</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Spect (004)]]>
                </title>
                <pubDate>Mon, 21 Jun 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8721795</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-spect-004-1</link>
                                <description>
                                            <![CDATA[<p>Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Spect (004)]]>
                </itunes:title>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702620/c1e-52po7umgg25f0jr8d-1xgg2v9rhg65-t74xdm.mp3" length="18532133"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:25:43</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Startup Profile: Cooler Heads (003)]]>
                </title>
                <pubDate>Wed, 16 Jun 2021 19:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8713826</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/startup-profile-cooler-heads-003-1</link>
                                <description>
                                            <![CDATA[<p>In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads. Kate shares how her personal experience battling cancer led to the creation of Cooler Heads produces a product to help those undergoing chemo treatment keep from losing their hair.<br /><br /></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads. Kate shares how her personal experience battling cancer led to the creation of Cooler Heads produces a product to help those undergoing chemo treatment keep from losing their hair.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Startup Profile: Cooler Heads (003)]]>
                </itunes:title>
                                    <itunes:episode>3</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads. Kate shares how her personal experience battling cancer led to the creation of Cooler Heads produces a product to help those undergoing chemo treatment keep from losing their hair.<br /><br /></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702622/c1e-64532c2wwrdsnwrv1-rommgjx2i4rq-lll9xe.mp3" length="28831875"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads. Kate shares how her personal experience battling cancer led to the creation of Cooler Heads produces a product to help those undergoing chemo treatment keep from losing their hair.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/65d77fbfef1e86-57254076/images/1702622/c1a-3q87p-8m778nz0ur1v-hozj8m.jpg"></itunes:image>
                                                                            <itunes:duration>00:40:02</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Venture Investing for Physicians (002)]]>
                </title>
                <pubDate>Sun, 13 Jun 2021 14:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8649931</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/venture-investing-for-physicians-002-1</link>
                                <description>
                                            <![CDATA[<p>In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned startup investor. Dr. Verret shares his lessons learned after making several dozen investments over the past decade.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned startup investor. Dr. Verret shares his lessons learned after making several dozen investments over the past decade.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Venture Investing for Physicians (002)]]>
                </itunes:title>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned startup investor. Dr. Verret shares his lessons learned after making several dozen investments over the past decade.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702623/c1e-0qgpztjoo06ugj2nm-2o118xr8tvj-qa95j8.mp3" length="35948818"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned startup investor. Dr. Verret shares his lessons learned after making several dozen investments over the past decade.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:49:54</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Innovation4Alpha Kick-Off (001)]]>
                </title>
                <pubDate>Fri, 28 May 2021 23:00:00 +0000</pubDate>
                <dc:creator>Innovation4Alpha</dc:creator>
                <guid isPermaLink="false">
                    Buzzsprout-8607737</guid>
                                    <link>https://innovation4alpha.castos.com/episodes/innovation4alpha-kick-off-001-1</link>
                                <description>
                                            <![CDATA[<p>This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Innovation4Alpha Kick-Off (001)]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                    <itunes:season>1</itunes:season>
                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/65d77fbfef1e86-57254076/1702624/c1e-x5d42im880xbnxr88-gdqqj7n5h5n9-gsg9xw.mp3" length="2799738"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:03:52</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Innovation4Alpha]]>
                </itunes:author>
                            </item>
            </channel>
</rss>
